WO2003101958A2 - Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors - Google Patents

Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors Download PDF

Info

Publication number
WO2003101958A2
WO2003101958A2 PCT/IB2003/002257 IB0302257W WO03101958A2 WO 2003101958 A2 WO2003101958 A2 WO 2003101958A2 IB 0302257 W IB0302257 W IB 0302257W WO 03101958 A2 WO03101958 A2 WO 03101958A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
amino
hydrochloride
syndrome
methyl
Prior art date
Application number
PCT/IB2003/002257
Other languages
French (fr)
Other versions
WO2003101958A3 (en
Inventor
Bernard Hulin
Janice Catherine Parker
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Priority to AU2003232405A priority Critical patent/AU2003232405A1/en
Priority to MXPA04011958A priority patent/MXPA04011958A/en
Priority to BR0311608-5A priority patent/BR0311608A/en
Priority to CA002487636A priority patent/CA2487636A1/en
Priority to JP2004509652A priority patent/JP2005533771A/en
Priority to EP03756085A priority patent/EP1513808A2/en
Publication of WO2003101958A2 publication Critical patent/WO2003101958A2/en
Publication of WO2003101958A3 publication Critical patent/WO2003101958A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38Halogen atoms or nitro radicals

Definitions

  • the present invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV (hereinafter "DPP-IV"), pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes, metabolic syndrome (Syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory fibroblastse
  • Dipeptidyl peptidase-IV (EC 3.4.14.5) is a serine protease that preferentially hydrolyzes an N-terminal dipeptide from proteins having proline or alanine in the 2 position.
  • the physiological role(s) of DPP-IV have not been fully elucidated, but it is believed to be involved in diabetes, glucose tolerance, obesity, appetite regulation, lipidemia, osteoporosis, neuropeptide metabolism and T-cell activation.
  • DPP-IV has been implicated in the control of glucose homeostasis because its substrates include the incretin peptides glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP). Cleavage of the N-terminal amino acids from these peptides renders them functionally inactive.
  • GLP-1 has been shown to be an effective anti-diabetic therapy in Type 2 diabetic patients and to reduce the meal- related insulin requirement in Type 1 diabetic patients.
  • GLP-1 and/or GIP are believed to regulate satiety, lipidemia and osteogenesis.
  • Exogenous GLP-1 has been proposed as a treatment for patients suffering from acute coronary syndrome, angina and ischemic heart disease.
  • DPP-IV inhibitors in vivo prevents N-terminal degradation of GLP-1 and GIP, resulting in higher circulating concentrations of these peptides, increased insulin secretion and improved glucose tolerance.
  • DPP-IV inhibitors are regarded as agents for the treatment of Type 2 diabetes, a disease in which glucose tolerance is impaired.
  • treatment with DPP-IV inhibitors prevents degradation of Neuropeptide Y (NPY), a peptide associated with a variety of central nervous system disorders, and Peptide YY which has been linked to gastrointestinal conditions such as ulcers, irritable bowel disease and inflammatory bowel disease.
  • NPY Neuropeptide Y
  • Peptide YY which has been linked to gastrointestinal conditions such as ulcers, irritable bowel disease and inflammatory bowel disease.
  • Treatment of Type 2 diabetes usually comprises a combination of diet, exercise, oral agents, and in more severe cases, insulin.
  • the clinically available hypoglycemics can have side effects which limit their use.
  • diabetes mellitus is a direct cause of the multiplicity of complications (cataracts, neuropathy, nephropathy, retinopathy, cardiomyopathy) that characterize advanced diabetes mellitus.
  • diabetes mellitus is a comorbid disease that frequently confounds hyperlipidemia, atherosclerosis and hypertension, adding significantly to the overall morbidity and mortality attributable to those diseases.
  • CVD cardiovascular disease
  • Hypertension is a condition that can occur in many patients in whom the causative agent or disorder is unknown. Such "essential" hypertension is often associated with disorders such as obesity, diabetes and hypertriglyceridemia, and it is known that hypertension is positively associated with heart failure, renal failure and stroke. Hypertension can also contribute to the development of atherosclerosis and coronary disease. Hypertension, together with insulin resistance and hyperlipidemia, comprise the constellation of symptoms that characterize Metabolic Syndrome, also known as insulin resistance syndrome (“IRS”) and syndrome X. Obesity is a well-known and common risk factor for the development of atherosclerosis, hypertension and diabetes. The incidence of obesity and hence of these diseases is increasing worldwide. Currently few pharmacological agents are available that reduce adiposity effectively and acceptably.
  • Osteoporosis is a progressive systemic disease characterized by low bone density and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. Osteoporosis and the consequences of compromised bone strength are a significant cause of frailty, and of increased morbidity and mortality.
  • Heart disease is a major health problem throughout the world. Myocardial infarctions are a significant source of mortality among those individuals with heart disease. Acute coronary syndrome denotes patients who have or are at high risk of developing an acute myocardial infarction (Ml). Though there are therapies available for the treatment of diabetes, hyperglycemia, hyperlipidemia, hypertension, obesity and osteoporosis there is a continuing need for alternative and improved therapies.
  • This invention is directed to compounds of Formula I which are useful for the treatment of Type 2 diabetes, metabolic syndrome (Syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes.
  • metabolic syndrome Syndrome X or insulin resistance syndrome
  • hyperglycemia impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic n
  • the invention is directed to a compound of the Formula I,
  • R 1 is 3-fluoroazetidin-1-yl, 3,3-difluoroazetidin-1-yl, 3,4-difluoropyrrolidin-1-yl, 3,3,4- trifluoropyrrolidin-1-yl, 3,3,4,4-tetrafluoropyrrolidin-1-yl, 3-f luoropiperid i n- 1 -y 1 , 4- fluoropiperidin-1-yl, 3,4-difluoropiperidin-1-yl, 3,5-difluoropiperidin-1-yl, 3,3- difluoropiperidin-1-yl, 4,4-difluoropiperidin-1-yl, 3,4,5-trifluoropiperidin-1-yl, 3,3,4- trifluoropiperidin-1-yl, 3,3,5-t ⁇ ' fluoropiperidin-1-yl, 3,4,4-thfluoropiperidin-1-yl, 3,3,4,5- tetrafluoropiperidin
  • the compound of Formula I is a compound wherein R 1 is 3-fluoroazetidin-1-yl or 3,3-difluoroazetidin-1-yl.
  • the compound of Formula I is a compound wherein R 1 is 3,4-difluoropyrrolidin-1-yl, 3,3,4-trifluoropyrrolidin-1-yl, 3,3,4,4- tetrafluoropyrrolidin-1 -yl.
  • the compound of Formula I is a compound wherein R 1 is 3-fluoropiperidin-1-yl, 4-fluoropiperidin-1-yl, 3,4-difluoropiperidin-1-yl, 3,5-difluoropiperidin-1-yl, 3,3-difluoropiperidin-1-yl or 4,4-difluoropiperidin-1-yl.
  • the compound of Formula I is a compound wherein R 1 is 3,4,5-trifluoropiperidin-1-yl, 3,3,4-trifluoropiperidin-1-yl, 3,3,5- trifluoropiperidin-1-yl, 3,4,4-trifluoropiperidin-1-yl, 3,3,4,5-tetrafluoropiperidin-1-yl, 3,4,4,5-tetrafluoropiperidin-1-yl, 3,3,4,4-tetrafluoropiperidin-l-yl 3,3,5,5- tetrafluoropiperidin-1 -yl, 3,3,4,5,5-pentafluoropiperidin-1 -yl, 3,3,4,4,5- pentafluoropiperidin-1 -yl or 3,3,4,4,5,5-hexafluoropiperidin-1 -yl.
  • the compound of Formula I is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I as described above, a prodrug thereof or a pharmaceutically acceptable salt of the compound or the prodrug, and a pharmaceutically acceptable diluent or carrier.
  • the invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of a first compound of Formula I as described above, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prordrug; and a second compound which is insulin or an insulin analog; insulinotropin; a biguanide; an ⁇ 2 -antagonist or an imidazoline; a glitazone; an aldose reductase inhibitor; a glycogen phosphorylase inhibitor; a sorbitol dehydrogenase inhibitor; a fatty acid oxidation inhibitor; an ⁇ -glucosidase inhibitor; a ⁇ -agonist; a phosphodiesterase inhibitor; a lipid-lowering agent; an antiobesity agent; vanadate, a vanadium complex or a peroxovanadium complex; an amylin antagonist; a glucagon antagonist; a growth hormone secretagogue; a gluconeogenesis inhibitor; a somato
  • the composition further comprises a pharmaceutically acceptable carrier or diluent.
  • the invention is directed to a kit comprising: a) a first dosage form comprising a compound of Formula I as described above; b) a second dosage form comprising an antidiabetic agent selected from insulin and insulin analogs; insulinotropin; biguanides; ⁇ 2 -antagonists and imidazolines; glitazones; aldose reductase inhibitors; glycogen phosphorylase inhibitors; sorbitol dehydrogenase inhibitors; fatty acid oxidation inhibitors; ⁇ -glucosidase inhibitors; ⁇ -agonists; phosphodiesterase inhibitors; lipid-lowering agents; antiobesity agents; vanadate and vanadium complexes and peroxovanadium complexes; amylin antagonists; glucagon antagonists; growth hormone secretagogues; gluconeogenesis inhibitors; somatostatin analog
  • the inventino is directed to a therapeutic method of inhibiting dipeptidyl peptidase-IV in a mammal, the method comprising administering to said mammal in need of inhibition of dipeptidyl peptidase-IV a therapeutically effective amount of a compound of Formula I as described above, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug; or of a pharmaceutical composition as described above.
  • the invention is directed to a therapeutic method of treating a condition mediated by dipeptidyl peptidase-IV inhibition in a mammal, the method comprising administering to said mammal suffering from a condition mediated by dipeptidyl peptidase-IV inhibition a therapeutically effective amount of a compound of Formula I as described above, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug; or a pharmaceutical composition as described above.
  • the condition treated is Type 2 diabetes, metabolic syndrome, hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, a condition exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, disease progression in Type 2 diabetes, chronic fatigue, epilepsy, a disease associated with intestinal motility, ulcer, irritable bowel syndrome, inflammatory bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, an eating disorder, chronic pain or alcohol addiction.
  • the condition treated is Type 2 diabetes mellitus.
  • the invention is directed to a method of identifying whether an agent is a DPP-IV inhibitor, comprising: a) administering the agent to a fasted, diabetic KK/H1J mouse; b) challenging the KK/H1J mouse with oral glucose; and c) assessing a response in the mouse to a subsequent oral glucose challenge, wherein said agent may be identified as a treatment for Type 2 diabetes, metabolic syndrome, hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, to prevent disease progression in Type 2 diabetes,
  • alkyl as used herein, means a saturated monovalent straight or branched aliphatic hydrocarbon radical having one to 8 carbon atoms.
  • pharmaceutically acceptable salt as used herein in relation to compounds of Formula I of this invention includes pharmaceutically acceptable anionic salts.
  • pharmaceutically acceptable anion refers to a negative ion that is compatible chemically and/or toxicologically with the other ingredients of a pharmaceutical composition and/or the animal being treated therewith.
  • Suitable anions include, but are not limited to, halides (e.g., chloride, iodide, and bromide), (C C 12 )alkylsulfonates (e.g., mesylate, ethylsulfonate, etc.), arylsulfonates (e.g., phenylsulfonate, tosylate, etc.), (CrC 12 )alkylphosphonates, di(C
  • C 12 )alkylphosphates e.g., dimethylphosphate, diethylphosphate, ⁇ -diglycerol phosphate, etc.
  • arylphosphonates arylphosphates, alkylarylphosphona.es, alkylarylphosphates, (d-C 12 )alkylcarboxylates (e.g., acetates, propionates, glutamates, glycerates, etc.), arylcarboxylates, and the like.
  • the compounds of the present invention may be isolated and used per se or in the form of its pharmaceutically acceptable salt, solvate and/or hydrate.
  • salts refers to inorganic and organic salts of a compound of the present invention.
  • salts can be prepared in situ during the final isolation and purification of a compound, or by separately reacting the compound, or prodrug with a suitable organic or inorganic acid and isolating the salt thus formed.
  • Representative salts include the hydrobromide, hydrochloride, hydroiodide, sulfate, bisulfate, nitrate, acetate, trifluoroacetate, oxalate, besylate, palmitiate, pamoate, malonate, stearate, laurate, malate, borate, benzoate, lactate, phosphate, hexafluorophosphate, benzene sulfonate, tosylate, formate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts, and the like. See, e.g., Berge, et al., J
  • prodrug means a compound that is transformed in vivo to yield a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvate of the compound.
  • Such compounds include, but are not limited to, N-acyl and N- carboalkoxy derivatives of Formula I compounds, as well as imine derivatives. The transformation may occur via various mechanisms, such as through hydrolysis in blood.
  • a discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
  • Some of the compounds described herein contain at least one stereogenic center; consequently, those skilled in the art will appreciate that all stereoisomers (e.g., enantiomers and diasteroisomers, and racemic mixtures thereof) of the compounds illustrated and discussed herein are within the scope of the present invention.
  • the carbon that is substituted with R 7 in compounds of Formula I, and its intermediates is stereogenic and these compounds are depicted and claimed in Claim 1 as racemic mixtures and in Claim 6 as the S enantiomers.
  • both the pyrrolidine and piperidine moieties of the compounds of Formula I may also contain at least one stereogenic center (e.g. Example 7). All stereoisomers (e.g., enantiomers and diasteroisomers, and racemic mixtures thereof) of these compounds claimed, illustrated and discussed herein are within the scope of the present invention.
  • the compounds of Formula I can exist in crystalline form as hydrates wherein molecules of water are incorporated within the crystal structure thereof and as solvates wherein molecules of a solvent are incorporated therein. All such hydrate and solvate forms are considered part of this invention.
  • This invention also includes isotopically-labeled compounds, which are identical to those described by Formula I, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen and fluorine, such as 2 H, 3 H, 13 C, 1 C, 15 N, 18 0, 17 O, and 18 F, respectively.
  • Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of the compounds or of the prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention.
  • isotopically-labeled compounds of the present invention for example those into which radioactive isotopes such as 3 H and 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated (i.e., 3 H), and carbon-14 (i.e., 14 C), isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2 H), can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances.
  • Isotopically labeled compounds of Formula I of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes and/or in the Examples below, by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
  • the compounds of Formula I of this invention may be prepared by methods that include processes known in the chemical arts, particularly in light of the description contained herein. Certain processes for the manufacture of the compounds of Formula I of this invention are illustrated by the following reaction schemes. Other processes are described in the experimental section. Some of the starting compounds for the reactions described in the schemes and Examples are prepared as illustrated herein. All other starting compounds may be obtained from general commercial sources, such as Sigma-Aldrich Corporation, St. Louis, MO.
  • the compounds of Formula I may be prepared (Step 1) by coupling (L) amino acid compounds of Formula II (e.g., (Z-)-Boc-isoleucine, (Z.)-Boc-cyclohexylgycine, (L)- Boc-allo-isoleucine, (L)-Boc-leucine, (L)-Boc-valine or (Z-)-Boc-alanine), wherein R 10 is a nitrogen-protecting group compatible with the above-described chemical Scheme I, with a compound of Formula III, a fluorinated pyrrolidine, (e.g. 3,3- difluoropyrrolidine hydrochloride or 3,3,4,4-tetrafluoropyrrolidine hydrochloride).
  • L amino acid compounds of Formula II
  • R 10 is a nitrogen-protecting group compatible with the above-described chemical Scheme I, with a compound of Formula III, a fluorinated pyrrolidine, (e.g. 3,3- di
  • Suitable nitrogen-protecting groups, R 10 may include for example, but are not limited to, fet ⁇ -butoxycarbonyl ("Boc"), benzyloxycarbonyl and fluorenylmethoxycarbonyl ("Fmoc”).
  • Boc fet ⁇ -butoxycarbonyl
  • Fmoc fluorenylmethoxycarbonyl
  • Other examples of nitrogen-protecting groups are described in "Protective Groups in Organic Synthesis", 2 nd . Ed., P.G.M. Wuts and T.W. Greene, p.315, incorporated herein by reference.
  • a compound of Formula IV, in Step 2 may be dissolved in an inert solvent (e.g.
  • ethyl acetate and deprotected by methods appropriate to the nature of the R 0 group, as described in the reference cited above (e.g. gaseous acid if R 10 is Boc), providing a compound of Formula I.
  • the coupling reaction described above is readily accomplished by dissolving a compound of Formula II and a compound of Formula III in a reaction inert solvent (e.g. dichloromethane) in the presence of base (e.g. triethylamine or pyridine).
  • base e.g. triethylamine or pyridine
  • a coupling agent or combination of coupling agents e.g. hydroxybenzotriazole / 1-(-3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.
  • coupling agents may be utilized, such as 1-hydroxy-7- azabenzotriazole / 1-(-3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, hydroxybenzotriazole /dicyclohexylcarbodiimide, 2-ethoxy-1-ethoxycarbonyl-1 ,2- dihydroquinoline, carbonyldiimidazole or diethylphosphorylcyanide.
  • the coupling is conducted in an inert solvent, preferably an aprotic solvent. Suitable solvents include, for example, acetonitrile, dichloromethane, dimethylformamide, chloroform.
  • the reaction is generally conducted at ambient pressure and temperature, until the starting materials are no longer present as determined by thin layer chromatography or other analytical techniques well known to those skilled in the art.
  • the coupled product of Formula IV may be isolated according to methods well known to those skilled in the art.
  • Deprotection of a compound of Formula IV readily occurs by dissolving a compound of Formula IV in an inert solvent (e.g. ethyl acetate) and cooling to about 0 ° C, followed by treatment with gaseous acid (e.g. hydrochloric acid) for about 1 minute. The reaction mixture is stirred for about 15 minutes and then allowed to reach room temperature, followed by stirring for about an additional 30 minutes.
  • an inert solvent e.g. ethyl acetate
  • gaseous acid e.g. hydrochloric acid
  • the protected (L) amino acid compound of Formula II depicted in Scheme III, and exemplified in Examples 2-8 may be replaced with a racemic mixture of a compound of Formula II. Consequently, the compounds of Formula I may exist as racemic mixtures of enantiomers and these mixtures are within the scope of this invention.
  • inert solvent is a solvent whose structure does not contain functional groups likely to interfere with the reaction.
  • examples for the activation of the hydroxyl groups and the coupling are dichloromethane, 1 ,2- dichloroethane, tetrahydrofuran (THF), dimethylformamide (DMF)
  • activating reagent in this instance is one that transforms a hydroxyl group into a leaving group such as bromide, iodide, alkylsulfonate or arylsulfonate
  • optically active amino acids may be obtained by resolution or by asymmetric synthesis or by other methods well known to those skilled in the art, prior to coupling in Step 1 of Schemes III. Alternatively, resolution, if so desired, may be accomplished at a later point in the synthesis of the compounds of Formula I by techniques known to those of ordinary skill in the art.
  • Compound III of Scheme I may be prepared as known to those of ordinary skill in the art.
  • 3,3-difluoropyrrolidine hydrochloride may be prepared as described by Giardina, G et al. Svnlett. 1995, 55.
  • 3,3,4,4-tetrafluoropyrrolidine may be prepared as described in Chaudry et al. J. Chem. Soc. 1964, 874.
  • 3,3,4,4-tetrafluoropyrrolidine may be prepared as depicted below in Scheme II.
  • Step 1 the hydroxyl groups of 2,2,3,3- tetrafluorobutanediol (X) are activated to a leaving group, R 8 , (wherein R 8 may be Br, I or SO 2 R 11 , wherein R 11 may either be (1) a C C 8 straight or branched alkyl, optionally substituted with one or several fluorines or (2) an aryl group, optionally substituted with halogen or a straight or branched alkyl optionally substituted with one to four fluorines).
  • R 8 is a trifluoromethylsulfonyloxy radical (F 3 CSO 3 ).
  • the activating reagents necessary to transform the alcohol function to, for example, bromine or iodine are well-known to those skilled in the art (see e.g. March, Advanced Organic Chemistry, 3 rd ed. pp. 382-384 and Larock, Comprehensive Organic Transformations, pp. 353-360, incorporated by reference) and include, but are not limited to, the following activating reagents: hydrogen bromide ("HBr"), phosphorus tribromide (“PBr 3 "), phosphorus pentabromide (“PBr 5 "), thionyl bromide ("SOBr 2 ”) and hydrogen iodide ("HI").
  • HBr hydrogen bromide
  • PBr 3 phosphorus tribromide
  • PBr 5 phosphorus pentabromide
  • SOBr 2 thionyl bromide
  • HI hydrogen iodide
  • Preferred activating reagent combinations are triphenylphosphine/carbon tetrabromide ("Ph 3 P/CBr 4 "), Ph 3 P/N- bromosuccinimide, potassium iodide/phosphoric acid ("KI/H 3 PO 4 "), Ph 3 P/l 2 and Me 3 SiCI/Nal.
  • Activation of the alcohol function to an alkyl or arylsulfonate is accomplished by reaction with the corresponding sulfonyl chloride or sulfonic anyhydride in an inert solvent in the presence of a base, such as pyridine or triethylamine, which is cooled (0"C) and stirred for about one hour. The reaction mixture is then stirred at room temperature for about an additional hour.
  • Step 2 the reaction of compound XI with a primary amine R 9 NH 2 , wherein R 9 is an alkyl or aryl "protecting" group (i.e., such that the bond linking R 9 to the nitrogen atom may be easily cleaved by standard chemical manipulation known to those skilled in the art in Step 3), is accomplished by heating the solution to reflux overnight.
  • R 9 is an alkyl or aryl "protecting" group (i.e., such that the bond linking R 9 to the nitrogen atom may be easily cleaved by standard chemical manipulation known to those skilled in the art in Step 3), is accomplished by heating the solution to reflux overnight.
  • N-protecting groups are described in "Protective Groups in Organic Synthesis", 2 nd . Ed., P.G.M. Wuts and T.W. Greene, p.362, incorporated herein by reference, and include, for example, benzyl, te/ ⁇ -butyl, allyl and benzhydryl.
  • R 9 is
  • Step 3 can be performed on a cationic salt of intermediate compound XII, such as hydrochloride, hydrobromide, acetate, trifluoroacetate etc., in an appropriate solvent (e.g. water, methanol or ethanol). Removal of the R 9 protecting group from compound XII may be accomplished under conditions appropriate for the particular R 9 protecting group in use.
  • a cationic salt of intermediate compound XII such as hydrochloride, hydrobromide, acetate, trifluoroacetate etc.
  • Such conditions include, for example, (a) hydrogenolysis where R 9 is benzyl or benzhydryl; (b) treatment with a strong acid, such as trifluoroacetic acid or hydrochloric acid, wherein R 9 is te/t-butyl; or (c) treatment with tributyltinhydride and acetic acid in the presence of catalytic bis(triphenylphosphine) palladium (II) chloride where R 9 is allyl.
  • a strong acid such as trifluoroacetic acid or hydrochloric acid
  • R 9 is benzyl
  • deprotection is performed by hydrogenolysis in the presence of 10% palladium in ethanol at about 45 psi for about 3 hours.
  • the final compound III is, thus, isolated as the corresponding cationic salt by filtration of the catalyst over diatomaceous earth, removal of the solvent and trituration with a non- hydroxylic solvent, such as diethyl ether, diisopropyl ether, ethyl acetate, 1 ,4- dioxane or tetrahydrofuran.
  • a non- hydroxylic solvent such as diethyl ether, diisopropyl ether, ethyl acetate, 1 ,4- dioxane or tetrahydrofuran.
  • Compound III is utilized, as described above in Scheme I, for preparation of DPP-IV inhibitor compounds of Formula I.
  • compounds of Formula I wherein a and b are each 0, may be prepared in accordance with the steps of Scheme III.
  • (L) amino acid compound of Formula II e.g. (Z-)-Boc-isoleucine
  • R 7 and R 10 are defined above
  • hydroxyazetidine the compound of Formula V
  • the resulting compound of Formula VI is treated, in Step 2, with diethylaminosulfur trifluoride or a similar fluorinating agent, providing a compound of Formula VII.
  • Step 3 a compound of Formula VII is treated with acid, as analogously described above in Step 2 of Scheme I, providing a compound of Formula I, wherein a and b are each zero.
  • the reaction described in Step 2 is readily accomplished by cooling a solution of diethylaminosulfur trifluoride (e.g. -78°C) in a reaction inert solvent (e.g. dichloromethane) to which a solution of the compound of Formula VI is added dropwise.
  • the reaction mixture is warmed to ambient temperatures, until the starting materials are no longer present or until the reaction is completed, as determined by thin layer chromatography or other analytical techniques well known to those skilled in the art.
  • the compound of Formula VII may be isolated according to methods well known to those skilled in the art and further treated with gaseous acid in Step 3, as analogously described above in Step 2 of Scheme I.
  • monofluoro pyrrolidine and piperidine derivatives can be prepared by a similar sequence, starting respectively with pyrrolidin-3-ol or a hydroxypiperidine.
  • compounds of Formula I can be prepared according to Scheme IV.
  • (L) amino acid compounds of Formula II e.g. (L)-Boc- isoleucine, Boc-cyclohexylglycine etc.
  • R 7 and R 10 are defined above
  • a compound of Formula VIII a fluorinated piperidine, wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are defined above, (e.g. 4,4-difluoro-piperidine hydrochloride), as analogously described above in Step 1 of Scheme I, forming the compound of Formula IX.
  • the compound of Formula IX, in Step 2 may be deprotected (e.g. gaseous acid), as analogously described in Step 2 of Scheme I, providing the compound of Formula I.
  • optically active amino acids may be obtained by resolution or by asymmetric synthesis or by other methods well known to those skilled in the art, prior to coupling in Step 1 of Schemes I, III and IV. Alternatively, resolution, if so desired, may be accomplished at a later point in the synthesis of the compounds of Formula I by techniques known to those of ordinary skill in the art.
  • the compounds of Formula I of the present invention are useful for the treatment of dipeptidyl peptidase-IV related conditions; the treatment of type II diabetes; the prevention of disease progression in type II diabetes; the treatment of type I diabetes, impaired glucose tolerance, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy and nephropathy, Metabolic Syndrome, obesity, the treatment of hypertension, hyperlipidemia, metabolic acidosis, arthritis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, short stature due to growth hormone deficiency, infertility due to polycystic ovary syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and short bowel syndrome.
  • the invention also relates to therapeutic methods for treating or preventing the above described conditions in a mammal, including a human, wherein a compound of Formula I of this invention is administered as part of an appropriate dosage regimen designed to obtain the benefits of the therapy.
  • the appropriate dosage regimen, the amount of each dose administered and the intervals between doses of the compound will depend upon the compound of Formula I of this invention being used, the type of pharmaceutical compositions being used, the characteristics of the subject being treated and the severity of the conditions.
  • an effective dosage for the compounds of Formula I described above is in the range of 0.01 mg/kg/day to 30 mg/kg/day, preferably 0.01 mg/kg/day to 1 mg/kg/day in single or divided doses. Some variation in dosage will necessarily occur, however, depending on the condition of the subject being treated. The individual responsible for dosing will, in any event, determine the appropriate dose for the individual subject.
  • the compounds of Formula I of this invention may be administered to a subject in need of treatment by a variety of conventional routes of administration, including orally and parenterally, (e.g., intravenously, subcutaneously or intramedullary). Further, the pharmaceutical compositions of this invention may be administered intranasally, as a suppository or using a "flash" formulation, i.e., allowing the medication to dissolve in the mouth without the need to use water.
  • the compounds of this invention may be administered in single (e.g., once daily) or multiple doses or via constant infusion.
  • the compounds of this invention may also be administered alone or in combination with pharmaceutically acceptable carriers, vehicles or diluents, in either single or multiple doses.
  • Suitable pharmaceutical carriers, vehicles and diluents include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents.
  • the pharmaceutical compositions formed by combining the compounds of this invention and the pharmaceutically acceptable carriers, vehicles or diluents are then readily administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, injectable solutions and the like.
  • These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like.
  • tablets containing various excipients such as sodium citrate, calcium carbonate and/or calcium phosphate may be employed along with various disintegrants such as starch, alginic acid and/or certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and/or acacia.
  • binding agents such as polyvinylpyrrolidone, sucrose, gelatin and/or acacia.
  • lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tabletting purposes.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols.
  • the active pharmaceutical agent therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and/or combinations thereof.
  • solutions of the compounds of this invention in sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solutions may be employed.
  • aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
  • the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
  • the compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • the pressurized container or nebulizer may contain a solution or suspension of a compound of this invention.
  • Capsules and cartridges for use in an inhaler or insufflator may be formulated containing a powder mix of a compound or compounds of the invention and a suitable powder base such as lactose or starch.
  • kits comprises two separate compositions: (1 ) a first dosage form comprising a compound of Formula I, a prodrug thereof, or pharmaceutically acceptable salts and prodrugs, plus a pharmaceutically acceptable diluent or carrier; and (2) a second dosage form comprising an antidiabetic agent selected from insulin and insulin analogs; insulinotropin; biguanides; ⁇ 2 -antagonists and imidazolines; glitazones; aldose reductase inhibitors; glycogen phosphorylase inhibitors; sorbitol dehydrogenase inhibitors; fatty acid oxidation inhibitors; ⁇ -glucosidase inhibitors; ff-agonists; phosphodiesterase inhibitors; lipid-lowering agents; antiobesity agents; vanadate and vana
  • the amounts of (1 ) and (2) are such that, when co-administered, the conditions, as described above, is treated or remediated.
  • the kit comprises a container for containing the separate dosage forms, such as a divided bottle or a divided foil packet, wherein each compartment contains a plurality of dosage forms (e.g. tablets) comprising (1 ) or (2).
  • the kit may contain separate compartments, each of which contains a whole dosage that in turn comprises separate dosage forms.
  • kits are blister pack wherein each individual blister contains two (or more) tablet(s) comprising pharmaceutical composition dosage form (1), and dosage form (2).
  • the kit comprises directions to the administration of the separate components.
  • the kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g. oral and parenteral), are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.
  • a kit therefore, comprises: d) a first dosage form comprising a compound of Formula I, a prodrug thereof, or a pharmaceutically acceptable salt or prodrug; e) a second dosage form comprising an antidiabetic agent selected from insulin and insulin analogs; insulinotropin; biguanides; ⁇ 2 -antagonists and imidazolines; glitazones; aldose reductase inhibitors; glycogen phosphorylase inhibitors; sorbitol dehydrogenase inhibitors; fatty acid oxidation inhibitors; ⁇ -glucosidase inhibitors; / ff-agonists; phosphodiesterase inhibitors; lipid-lowering agents; antiobesity agents; vanadate and vanadium complexes and peroxovanadium complexes; amylin antagonists; glucagon antagonists; growth hormone secretagogues; gluconeogenesis inhibitors; somatostatin analogs; inhibitors of renal glucose
  • the dipeptidyl peptidase inhibition may be demonstrated in vitro by the following assay, which is adapted from published methods for the measurement of
  • DPP-IV activity (Assay of dipeptidyl peptidase IV in serum by fluorometry of 4- methoxy-2-naphthylamide. (1988) Scharpe, S., DeMeester, I., Vanhoof, G., Hendriks, D., Van Sande, M., Van Camp, K. and Yaron, A. Clin. Chem. 34:2299-2301 ; Dipeptidyl peptidases of human lymphocytes (1988) Lodja, Z.
  • Substrate solution comprising 50 ⁇ M Gly-Pro-4-methoxy B naphthylamide HCI (e.g.182 ⁇ g Gly-Pro-4-methoxy B naphthylamide HCI per 10 mL 50mM Tris assay buffer pH 7.3 containing 0.1 M sodium chloride, 0.1 % (v/v) Triton and enzyme (Enzyme Systems Products Cat#SPE-01 , DPP-IV 5 mU/mL stock) diluted 1 :100 (100 ⁇ L enzyme per 10 mL substrate solution), forming an enzyme substrate solution that is maintained at 4°C.
  • Tris assay buffer pH 7.3 containing 0.1 M sodium chloride, 0.1 % (v/v) Triton and enzyme (Enzyme Systems Products Cat#SPE-01 , DPP-IV 5 mU/mL stock) diluted 1 :100 (100 ⁇ L enzyme per 10 mL substrate solution), forming an enzyme substrate solution that is maintained at 4°C.
  • 150 ⁇ L of the enzyme substrate solution is pipetted into microtiter wells of a polystyrene 96-well plate, and maintained at 4°C. 5 ⁇ Uwell of compounds of Formula I are added, bringing the final compound of Formula I concentrations to 3 ⁇ M - 10 nM per well.
  • Enzyme is omitted from four (4) wells, as a reagent blank. 5 ⁇ L of 3 mM Diprotin A is added to four wells as a positive quality control, providing a final Diprotin A concentration of 100 ⁇ M. To measure total enzyme activity (i.e. a negative control), without the influence of any compounds of Formula I, 5 ⁇ L of distilled water is added to four wells.
  • the entire assay is incubated overnight (about 14-18 hours) at 37°C.
  • the reaction is quenched by adding 10 ⁇ L of Fast Blue B solution (0.5 mg/mL Fast Blue B in a buffer comprising 0.1 M sodium acetate pH 4.2 and 10% (v/v) Triton X-100 to each well, followed by shaking for approximately 5 minutes at room temperature.
  • Fast Blue B solution 0.5 mg/mL Fast Blue B in a buffer comprising 0.1 M sodium acetate pH 4.2 and 10% (v/v) Triton X-100
  • IC 50 data for compounds may be obtained by measuring the activity of DPP-IV over a range of compound concentrations from 10nM to 3 ⁇ M.
  • Oral glucose tolerance tests have been in use in humans since, at least, the 1930's, Pincus et al., Am. J. Med. Sci, 188: 782 (1934), and is routinely used in the diagnosis of human diabetes, though, not to evaluate the efficacy of therapeutic agents in patients.
  • KK mice have been used to evaluate glitazones (Fujita et al. Diabetes 32:804-
  • KK mice are derived from an inbred line first established by Kondo et al.
  • mice spontaneously develop a hereditary form of polygenic diabetes that progresses to cause renal, retinal and neurological complications analogous to those seen in human diabetic subjects, but they do not require insulin or other medication for survival.
  • the invention is directed to the use of KK mice to evaluate the effects of insulin secretagogue agents in the context of an oral glucose tolerance test.
  • KK mice In Vivo Assay for Glucose Lowering
  • mice (10 per group) are then orally dosed with a solution of a compound of Formula I in 0.5% methylcellulose (0.2 mL/mouse).
  • Two controls groups receive only 0.5% methylcellulose.
  • the mice are bled, as described above, and then dosed with 1 mg/kg glucose in distilled water (0.2 mL/mouse).
  • the first control group is dosed with glucose.
  • the second control group is dosed with water.
  • mice 45 minutes, the mice are again bled, as described above.
  • the blood samples are centrifuged, the plasma collected and analyzed for glucose content on a Roche- Hitachi 912 glucose analyzer. The data may be expressed as percent (%) inhibition of glucose excursion relative to the two control groups (i.e. the glucose level in the animals receiving glucose but no test compound representing 0% inhibition and the glucose concentration in the animals receiving only water representing 100% inhibition).
  • Step 1 1S, 2S.-2-MethvM-(3.3.4.4-tetrafluoro-pyrroMdine-1-carbonyl,-butyll- carbamic acid tert-butyl ester.
  • Step 2 (2S, 3S)-2-amino-3-methyl-1-(3,3,4.4-tetrafluoro-pyrrolidin-1-yl)-pentan- 1-one hydrochloride.
  • [(1S, 2S)-2-Methyl-1-(3,3,4,4-tetrafluoro-pyrrolidine-1-carbonyl)-butyl]- carbamic acid tert-butyl ester 200 mg, 0.56 mmol
  • was dissolved in ethyl acetate (4 mL) cooled to 0°C and treated with gaseous HCI for about 1 minute. After 15 minute at 0°C and 30 minute at room temperature, the mixture was concentrated to dryness and the solid was triturated with hexane, collected and dried under vacuum overnight (124 mg, 76%, mp > 250 °C).
  • Step 1 r(7S,2S)-1-(3-Hvdroxy-azetidine-1-carbonyl,-2-methyl-butyll-carbamic acid te/f-butyl ester.
  • (2S,3S)-2-amino-1-(3-fluoro-azetidin-1-yl)-3-methyl-pentan-1-one was prepared by HCI treatment of [(7S,2S)-1-(3-fluoro-azetidine-1-carbonyl)-2-methyl- butylj-carbamic acid te/f-butyl ester as analogously described in Step 2 of Example 1. (mp 208-210 °C).
  • Step 1 (SH1-Cvclohexyl-2-oxo-2-,3.3A4-tetrafluoro-pyrrolidin-1-yl)-ethyll- carbamic acid te/f-butyl ester.
  • Step 1 ⁇ (1 S.2/?.-2-Methyl-1 -(3.3.4.4-tetraf luoro-pyrrolidine-1 -carbonyl.-butyll- carbamic acid te/f-butyl ester.
  • (2S,3R)-2-amino-1-(3,3-difluoro-pyrrolidin-1-yl)-3-methyl-pentan-1-one was prepared from 3,3-difluropyrrolidine hydrochloride (prepared according to Giardina, G. Synlett 1995, 55) and ( )-Boc-isoleucine, as analogously described in Example 1 (mp 196-198 °C).
  • (2S, 3S)-2-amino-1 -(3,3-difluoro-pyrrolidin-1 -yl)-3-methyl-pentan-1 -one was prepared from 3,3-difluropyrrolidine hydrochloride and ( )-Boc-isoleucine, as analogously described in Example 7 (mp 195-198 °C).
  • 4,4-Difluoro-piperidine hydrochloride obtained by HCI treatment of 4,4- difluoro-piperidine-1-carboxylic acid tert-butyl ester (as described in WO0040561 ), was coupled with Boc-( .)-cyclohexylglycine followed by HCI deprotection, as analogously described in Example 1 (mp > 250 °C).
  • Step 1 Trifluoro-methanesulfonic acid 2.2,3.3-tetrafluoro-4-(trifluoro- methanesulfonyloxy)-butyl ester.
  • Step 3 3.3.4.4-Tetrafluoro-pyrrolidine hydrochloride.
  • a solution of 1-benzyl-3,3,4,4-tetrafluoro-pyrrolidine hydrochloride (23.8 g, 88 mmol) in ethanol (300 mL) containing 10% palladium on carbon was treated with hydrogen in a Parr shaker at 45 psi for 3 hours. The mixture was filtered through Celite®, the filtrate was concentrated to dryness. The residue was triturated with ether and the solid was collected and dried (13.4 g, 85%, (mp 193-196 °C).

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)

Abstract

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

Description

FLUORINATED CYCLIC AMIDES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS
Field of the Invention The present invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV (hereinafter "DPP-IV"), pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes, metabolic syndrome (Syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.
Background of the Invention Dipeptidyl peptidase-IV (EC 3.4.14.5) is a serine protease that preferentially hydrolyzes an N-terminal dipeptide from proteins having proline or alanine in the 2 position. The physiological role(s) of DPP-IV have not been fully elucidated, but it is believed to be involved in diabetes, glucose tolerance, obesity, appetite regulation, lipidemia, osteoporosis, neuropeptide metabolism and T-cell activation.
DPP-IV has been implicated in the control of glucose homeostasis because its substrates include the incretin peptides glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP). Cleavage of the N-terminal amino acids from these peptides renders them functionally inactive. GLP-1 has been shown to be an effective anti-diabetic therapy in Type 2 diabetic patients and to reduce the meal- related insulin requirement in Type 1 diabetic patients. GLP-1 and/or GIP are believed to regulate satiety, lipidemia and osteogenesis. Exogenous GLP-1 has been proposed as a treatment for patients suffering from acute coronary syndrome, angina and ischemic heart disease.
Administration of DPP-IV inhibitors in vivo prevents N-terminal degradation of GLP-1 and GIP, resulting in higher circulating concentrations of these peptides, increased insulin secretion and improved glucose tolerance. On the basis of these observations, DPP-IV inhibitors are regarded as agents for the treatment of Type 2 diabetes, a disease in which glucose tolerance is impaired. In addition, treatment with DPP-IV inhibitors prevents degradation of Neuropeptide Y (NPY), a peptide associated with a variety of central nervous system disorders, and Peptide YY which has been linked to gastrointestinal conditions such as ulcers, irritable bowel disease and inflammatory bowel disease.
In spite of the early discovery of insulin and its subsequent widespread use in the treatment of diabetes, and the later discovery of and use of sulfonylureas (e. f. chlorpropamide (Pfizer), tolbutamide (Upjohn), acetohexamide (E.I.Lilly)), biguanides (Phenformin (Ciba Geigy), metformin (G.D. Searle)) and thiazolidinediones (rosiglitazone (GlaxoSmithKline, Bristol-MyersSquibb), pioglitazone (Takeda, E.I. Lilly)) as oral hypoglycemic agents, the treatment of diabetes remains less than satisfactory.
The use of insulin, necessary in Type 1 diabetic patients and about 10% of Type 2 diabetic patients in whom currently available oral hypoglycemic agents are ineffective, requires multiple daily doses, usually by self-injection. Determination of the appropriate dosage of insulin necessitates frequent estimations of the glucose concentration in urine or blood. The administration of an excess dose of insulin causes hypoglycemia, with consequences ranging from mild abnormalities in blood glucose to coma, or even death.
Treatment of Type 2 diabetes usually comprises a combination of diet, exercise, oral agents, and in more severe cases, insulin. However, the clinically available hypoglycemics can have side effects which limit their use. A continuing need for hypoglycemic agents, which may have fewer side effects or succeed where others fail, is clearly evident.
Poorly controlled hyperglycemia is a direct cause of the multiplicity of complications (cataracts, neuropathy, nephropathy, retinopathy, cardiomyopathy) that characterize advanced diabetes mellitus. In addition, diabetes mellitus is a comorbid disease that frequently confounds hyperlipidemia, atherosclerosis and hypertension, adding significantly to the overall morbidity and mortality attributable to those diseases.
Epidemiological evidence has firmly established hyperlipidemia as a primary risk factor for cardiovascular disease ("CVD") due to atherosclerosis. Atherosclerosis is recognized to be a leading cause of death in the United States and Western Europe. CVD is especially prevalent among diabetic subjects, at least in part because of the existence of multiple independent risk factors such as glucose intolerance, left ventricular hypertrophy and hypertension in this population. Successful treatment of hyperlipidemia in the general population, and in diabetic subjects in particular, is therefore of exceptional medical importance.
Hypertension (or high blood pressure) is a condition that can occur in many patients in whom the causative agent or disorder is unknown. Such "essential" hypertension is often associated with disorders such as obesity, diabetes and hypertriglyceridemia, and it is known that hypertension is positively associated with heart failure, renal failure and stroke. Hypertension can also contribute to the development of atherosclerosis and coronary disease. Hypertension, together with insulin resistance and hyperlipidemia, comprise the constellation of symptoms that characterize Metabolic Syndrome, also known as insulin resistance syndrome ("IRS") and syndrome X. Obesity is a well-known and common risk factor for the development of atherosclerosis, hypertension and diabetes. The incidence of obesity and hence of these diseases is increasing worldwide. Currently few pharmacological agents are available that reduce adiposity effectively and acceptably.
Osteoporosis is a progressive systemic disease characterized by low bone density and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. Osteoporosis and the consequences of compromised bone strength are a significant cause of frailty, and of increased morbidity and mortality.
Heart disease is a major health problem throughout the world. Myocardial infarctions are a significant source of mortality among those individuals with heart disease. Acute coronary syndrome denotes patients who have or are at high risk of developing an acute myocardial infarction (Ml). Though there are therapies available for the treatment of diabetes, hyperglycemia, hyperlipidemia, hypertension, obesity and osteoporosis there is a continuing need for alternative and improved therapies.
SUMMARY OF INVENTION
This invention is directed to compounds of Formula I which are useful for the treatment of Type 2 diabetes, metabolic syndrome (Syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes.
In particular, the invention is directed to a compound of the Formula I,
Figure imgf000005_0001
a prodrug thereof, or a pharmaceutically acceptable salt of the compound or the prodrug, wherein:
R1 is 3-fluoroazetidin-1-yl, 3,3-difluoroazetidin-1-yl, 3,4-difluoropyrrolidin-1-yl, 3,3,4- trifluoropyrrolidin-1-yl, 3,3,4,4-tetrafluoropyrrolidin-1-yl, 3-f luoropiperid i n- 1 -y 1 , 4- fluoropiperidin-1-yl, 3,4-difluoropiperidin-1-yl, 3,5-difluoropiperidin-1-yl, 3,3- difluoropiperidin-1-yl, 4,4-difluoropiperidin-1-yl, 3,4,5-trifluoropiperidin-1-yl, 3,3,4- trifluoropiperidin-1-yl, 3,3,5-tπ'fluoropiperidin-1-yl, 3,4,4-thfluoropiperidin-1-yl, 3,3,4,5- tetrafluoropiperidin-1-yl, 3,4,4,5-tetrafluoropiperidin-1-yl, 3,3,4,4-tetrafluoropiperidin-1- yl 3,3,5,5-tetrafluoropiperidin-1-yl, 3,3,4,5,5-pentafluoropiperidin-1-yl, 3,3,4,4,5- pentafluoropiperidin-1-yl or 3,3,4,4,5,5-hexafluoropiperidin-1-yl; and R2 is (C C8)alkyl or (C3-C8)cycloalkyl.
In a preferred embodiment, the compound of Formula I is a compound wherein R1 is 3-fluoroazetidin-1-yl or 3,3-difluoroazetidin-1-yl.
In another preferred embodiment, the compound of Formula I is a compound wherein R1 is 3,4-difluoropyrrolidin-1-yl, 3,3,4-trifluoropyrrolidin-1-yl, 3,3,4,4- tetrafluoropyrrolidin-1 -yl.
In another preferred embodiment, the compound of Formula I is a compound wherein R1 is 3-fluoropiperidin-1-yl, 4-fluoropiperidin-1-yl, 3,4-difluoropiperidin-1-yl, 3,5-difluoropiperidin-1-yl, 3,3-difluoropiperidin-1-yl or 4,4-difluoropiperidin-1-yl. In another preferred embodiment, the compound of Formula I is a compound wherein R1 is 3,4,5-trifluoropiperidin-1-yl, 3,3,4-trifluoropiperidin-1-yl, 3,3,5- trifluoropiperidin-1-yl, 3,4,4-trifluoropiperidin-1-yl, 3,3,4,5-tetrafluoropiperidin-1-yl, 3,4,4,5-tetrafluoropiperidin-1-yl, 3,3,4,4-tetrafluoropiperidin-l-yl 3,3,5,5- tetrafluoropiperidin-1 -yl, 3,3,4,5,5-pentafluoropiperidin-1 -yl, 3,3,4,4,5- pentafluoropiperidin-1 -yl or 3,3,4,4,5,5-hexafluoropiperidin-1 -yl.
In another preferred embodiment, the compound of Formula I is
(2S,3S)-2-amino-3-methyl-1-(3,3,4,4-tetrafluoro-pyrrolidin-1-yl)-pentan-1- one hydrochloride;
(2S,3S)-2-amino-1-(3-fluoro-azetidin-1-yl)-3-methyl-pentan-1-one hydrochloride;
(S)-2-amino-2-cyclohexyl-1-(3,3,4,4-tetrafluoro-pyrrolidin-1-yl)-ethanone hydrochloride;
(2S,3 ?)-2-amino-3-methyl-1-(3,3,4,4-tetrafluoro-pyrrolidin-1-yl)-pentan-1- one hydrochloride; (S)-2-amino-2-cyclohexyl-1 -(3-fluoro-azetidin-1 -yl)-ethanone hydrochloride;
(S)-2-amino-3-methyl-1-(3,3,4,4-tetrafluoro-pyrrolidin-1-yl)-butan-1-one hydrochloride;
(S)-2-amino-4-methyl-1 -(3,3,4,4-tetrafluoro-pyrrolidin-1 -yl)-pentan-1 -one hydrochloride;
(S)-2-amino-2-cyclohexyl-1-(3,3-difluoro-azetidin-1-yl)-ethanone hydrochloride;
(2S,3S)-2-amino-1-(3,3-difluoro-azetidin-1-yl)-3-methyl-pentan-1-one hydrochloride; (S)-2-amino-2-cyclohexyl-1-(4,4-difluoro-piperidin-1-yl)-ethanone hydrochloride;
(2S,3S)-2-amino-1 -(4,4-difluoro-piperidin-1 -yl)-3-methyl-pentan-1 -one hydrochloride; (S)-2-amino-1 -(3,3,4,4-tetrafluoro-pyrrolidin-1 -yl)-propan-1 -one hydrochloride;
(S)-2-amino-1-(3,3-difluoro-azetidin-1-yl)-3-methyl-butan-1-one hydrochloride;
(S)-2-amino-1 -(3-fluoro-azetidin-1 -yl)-3-methyl-butan-1 -one hydrochloride; (2S,3R)-2-amino-1-(3-fluoro-azetidin-1-yl)-3-methyl-pentan-1-one hydrochloride;
(2S,3fi)-2-amino-1 -(3,3-difluoro-azetidin-1 -yl)-3-methyl-pentan-1 -one hydrochloride;
(S)-2-amino-2-cyclopentyl-1-(3,3-difluoro-azetidin-1-yl)-ethanone hydrochloride;
(S)-2-amino-2-cyclopentyl-1-(3-fluoro-azetidin-1-yl)-ethanone hydrochloride; or
(S)-2-amino-2-cyclopentyl-1-(3,3,4,4-tetrafluoro-pyrrolidin-1-yl)-ethanone hydrochloride.
In another preferred embodiment, the compound of Formula I,
Figure imgf000007_0001
is a S enantiomer, as shown.
In another aspect, the invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I as described above, a prodrug thereof or a pharmaceutically acceptable salt of the compound or the prodrug, and a pharmaceutically acceptable diluent or carrier. ln yet another aspect, the invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of a first compound of Formula I as described above, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prordrug; and a second compound which is insulin or an insulin analog; insulinotropin; a biguanide; an σ2-antagonist or an imidazoline; a glitazone; an aldose reductase inhibitor; a glycogen phosphorylase inhibitor; a sorbitol dehydrogenase inhibitor; a fatty acid oxidation inhibitor; an σ-glucosidase inhibitor; a ^-agonist; a phosphodiesterase inhibitor; a lipid-lowering agent; an antiobesity agent; vanadate, a vanadium complex or a peroxovanadium complex; an amylin antagonist; a glucagon antagonist; a growth hormone secretagogue; a gluconeogenesis inhibitor; a somatostatin analog; an inhibitor of renal glucose; or an antilipolytic agent; a prodrug of the second compound or a pharmaceutically acceptable salt of the second compound or of the prodrug of the second compound. In another embodiment of this aspect of the invention, the composition further comprises a pharmaceutically acceptable carrier or diluent. In another aspect, the invention is directed to a kit comprising: a) a first dosage form comprising a compound of Formula I as described above; b) a second dosage form comprising an antidiabetic agent selected from insulin and insulin analogs; insulinotropin; biguanides; σ2-antagonists and imidazolines; glitazones; aldose reductase inhibitors; glycogen phosphorylase inhibitors; sorbitol dehydrogenase inhibitors; fatty acid oxidation inhibitors; σ-glucosidase inhibitors; ^-agonists; phosphodiesterase inhibitors; lipid-lowering agents; antiobesity agents; vanadate and vanadium complexes and peroxovanadium complexes; amylin antagonists; glucagon antagonists; growth hormone secretagogues; gluconeogenesis inhibitors; somatostatin analogs; inhibitors of renal glucose; antilipolytic agents; prodrugs of the second dosage form and pharmaceutically acceptable salts of the second dosage form and the prodrugs; and c) a container means for containing said first dosage (a) and said second dosage (b). In one embodiment, the kit further comprising a pharmaceutically acceptable carrier or diluent and a container means for said carrier or diluent.
In another aspect, the inventino is directed to a therapeutic method of inhibiting dipeptidyl peptidase-IV in a mammal, the method comprising administering to said mammal in need of inhibition of dipeptidyl peptidase-IV a therapeutically effective amount of a compound of Formula I as described above, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug; or of a pharmaceutical composition as described above. In another aspect, the invention is directed to a therapeutic method of treating a condition mediated by dipeptidyl peptidase-IV inhibition in a mammal, the method comprising administering to said mammal suffering from a condition mediated by dipeptidyl peptidase-IV inhibition a therapeutically effective amount of a compound of Formula I as described above, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug; or a pharmaceutical composition as described above.
In one embodiment of the methods, the condition treated is Type 2 diabetes, metabolic syndrome, hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, a condition exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, disease progression in Type 2 diabetes, chronic fatigue, epilepsy, a disease associated with intestinal motility, ulcer, irritable bowel syndrome, inflammatory bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, an eating disorder, chronic pain or alcohol addiction.
In a preferred embodiment, the condition treated is Type 2 diabetes mellitus. In another aspect, the invention is directed to a method of identifying whether an agent is a DPP-IV inhibitor, comprising: a) administering the agent to a fasted, diabetic KK/H1J mouse; b) challenging the KK/H1J mouse with oral glucose; and c) assessing a response in the mouse to a subsequent oral glucose challenge, wherein said agent may be identified as a treatment for Type 2 diabetes, metabolic syndrome, hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, to prevent disease progression in Type 2 diabetes, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome or short bowel syndrome.
The term "alkyl" as used herein, means a saturated monovalent straight or branched aliphatic hydrocarbon radical having one to 8 carbon atoms.
The expression "pharmaceutically acceptable salt" as used herein in relation to compounds of Formula I of this invention includes pharmaceutically acceptable anionic salts. The term "pharmaceutically acceptable anion" refers to a negative ion that is compatible chemically and/or toxicologically with the other ingredients of a pharmaceutical composition and/or the animal being treated therewith. Suitable anions include, but are not limited to, halides (e.g., chloride, iodide, and bromide), (C C12)alkylsulfonates (e.g., mesylate, ethylsulfonate, etc.), arylsulfonates (e.g., phenylsulfonate, tosylate, etc.), (CrC12)alkylphosphonates, di(C
C12)alkylphosphates (e.g., dimethylphosphate, diethylphosphate, α-diglycerol phosphate, etc.), arylphosphonates, arylphosphates, alkylarylphosphona.es, alkylarylphosphates, (d-C12)alkylcarboxylates (e.g., acetates, propionates, glutamates, glycerates, etc.), arylcarboxylates, and the like. The compounds of the present invention may be isolated and used per se or in the form of its pharmaceutically acceptable salt, solvate and/or hydrate. The term "salts" refers to inorganic and organic salts of a compound of the present invention. These salts can be prepared in situ during the final isolation and purification of a compound, or by separately reacting the compound, or prodrug with a suitable organic or inorganic acid and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, hydroiodide, sulfate, bisulfate, nitrate, acetate, trifluoroacetate, oxalate, besylate, palmitiate, pamoate, malonate, stearate, laurate, malate, borate, benzoate, lactate, phosphate, hexafluorophosphate, benzene sulfonate, tosylate, formate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts, and the like. See, e.g., Berge, et al., J. Pharm. Sci., 66, 1-19 (1977).
The term "prodrug" means a compound that is transformed in vivo to yield a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvate of the compound. Such compounds include, but are not limited to, N-acyl and N- carboalkoxy derivatives of Formula I compounds, as well as imine derivatives. The transformation may occur via various mechanisms, such as through hydrolysis in blood. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
Some of the compounds described herein contain at least one stereogenic center; consequently, those skilled in the art will appreciate that all stereoisomers (e.g., enantiomers and diasteroisomers, and racemic mixtures thereof) of the compounds illustrated and discussed herein are within the scope of the present invention. In particular, the carbon that is substituted with R7 in compounds of Formula I, and its intermediates, is stereogenic and these compounds are depicted and claimed in Claim 1 as racemic mixtures and in Claim 6 as the S enantiomers. One skilled in the art will also recognize that both the pyrrolidine and piperidine moieties of the compounds of Formula I may also contain at least one stereogenic center (e.g. Example 7). All stereoisomers (e.g., enantiomers and diasteroisomers, and racemic mixtures thereof) of these compounds claimed, illustrated and discussed herein are within the scope of the present invention.
Those skilled in the art will further recognize that the compounds of Formula I can exist in crystalline form as hydrates wherein molecules of water are incorporated within the crystal structure thereof and as solvates wherein molecules of a solvent are incorporated therein. All such hydrate and solvate forms are considered part of this invention.
This invention also includes isotopically-labeled compounds, which are identical to those described by Formula I, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen and fluorine, such as 2H, 3H, 13C, 1 C, 15N, 180, 17O, and 18F, respectively. Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of the compounds or of the prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically-labeled compounds of the present invention, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated (i.e., 3H), and carbon-14 (i.e., 14C), isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2H), can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labeled compounds of Formula I of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes and/or in the Examples below, by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
DESCRIPTION OF INVENTION In general, the compounds of Formula I of this invention may be prepared by methods that include processes known in the chemical arts, particularly in light of the description contained herein. Certain processes for the manufacture of the compounds of Formula I of this invention are illustrated by the following reaction schemes. Other processes are described in the experimental section. Some of the starting compounds for the reactions described in the schemes and Examples are prepared as illustrated herein. All other starting compounds may be obtained from general commercial sources, such as Sigma-Aldrich Corporation, St. Louis, MO.
SCHEME I
ι Coupling Agent
Figure imgf000013_0001
2 Deprotection
Figure imgf000013_0002
Figure imgf000013_0003
According to Scheme I, the compounds of Formula I, wherein R1, R2, R3, R4 and R7 are defined above, may be prepared (Step 1) by coupling (L) amino acid compounds of Formula II (e.g., (Z-)-Boc-isoleucine, (Z.)-Boc-cyclohexylgycine, (L)- Boc-allo-isoleucine, (L)-Boc-leucine, (L)-Boc-valine or (Z-)-Boc-alanine), wherein R10 is a nitrogen-protecting group compatible with the above-described chemical Scheme I, with a compound of Formula III, a fluorinated pyrrolidine, (e.g. 3,3- difluoropyrrolidine hydrochloride or 3,3,4,4-tetrafluoropyrrolidine hydrochloride).
Suitable nitrogen-protecting groups, R10, may include for example, but are not limited to, fetτ-butoxycarbonyl ("Boc"), benzyloxycarbonyl and fluorenylmethoxycarbonyl ("Fmoc"). Other examples of nitrogen-protecting groups are described in "Protective Groups in Organic Synthesis", 2nd. Ed., P.G.M. Wuts and T.W. Greene, p.315, incorporated herein by reference. When the coupling is performed using a compound of Formula II, a compound of Formula IV is produced. A compound of Formula IV, in Step 2, may be dissolved in an inert solvent (e.g. ethyl acetate) and deprotected by methods appropriate to the nature of the R 0 group, as described in the reference cited above (e.g. gaseous acid if R10 is Boc), providing a compound of Formula I. The coupling reaction described above is readily accomplished by dissolving a compound of Formula II and a compound of Formula III in a reaction inert solvent (e.g. dichloromethane) in the presence of base (e.g. triethylamine or pyridine). To the resulting solution, is added a coupling agent or combination of coupling agents (e.g. hydroxybenzotriazole / 1-(-3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride). Other coupling agents may be utilized, such as 1-hydroxy-7- azabenzotriazole / 1-(-3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, hydroxybenzotriazole /dicyclohexylcarbodiimide, 2-ethoxy-1-ethoxycarbonyl-1 ,2- dihydroquinoline, carbonyldiimidazole or diethylphosphorylcyanide. The coupling is conducted in an inert solvent, preferably an aprotic solvent. Suitable solvents include, for example, acetonitrile, dichloromethane, dimethylformamide, chloroform. For a discussion of other conditions useful for coupling carboxylic acids see Houben-Weyl, Vol XV, part II, E. Wunsch, Ed., G. Theime Verlag, 1974, Stuttgart, and those described in M. Bodansky, Principles of Peptide Synthesis, Springer- Verlag Berlin 1984, and The peptides. Analysis , Synthesis and Biology (ed. E. Gross and J. Meienhofer), vols 1-5 (Academic Press NY 1979-1983). The text of the above references are incorporated by reference.
The reaction is generally conducted at ambient pressure and temperature, until the starting materials are no longer present as determined by thin layer chromatography or other analytical techniques well known to those skilled in the art. The coupled product of Formula IV may be isolated according to methods well known to those skilled in the art.
Deprotection of a compound of Formula IV readily occurs by dissolving a compound of Formula IV in an inert solvent (e.g. ethyl acetate) and cooling to about 0°C, followed by treatment with gaseous acid (e.g. hydrochloric acid) for about 1 minute. The reaction mixture is stirred for about 15 minutes and then allowed to reach room temperature, followed by stirring for about an additional 30 minutes. One of ordinary skill in the art will appreciate that the protected (L) amino acid compound of Formula II depicted in Scheme III, and exemplified in Examples 2-8, may be replaced with a racemic mixture of a compound of Formula II. Consequently, the compounds of Formula I may exist as racemic mixtures of enantiomers and these mixtures are within the scope of this invention.
As used herein, the term "inert solvent" is a solvent whose structure does not contain functional groups likely to interfere with the reaction. Examples for the activation of the hydroxyl groups and the coupling are dichloromethane, 1 ,2- dichloroethane, tetrahydrofuran (THF), dimethylformamide (DMF)
As used herein, the term "activating reagent" in this instance is one that transforms a hydroxyl group into a leaving group such as bromide, iodide, alkylsulfonate or arylsulfonate
The optically active amino acids may be obtained by resolution or by asymmetric synthesis or by other methods well known to those skilled in the art, prior to coupling in Step 1 of Schemes III. Alternatively, resolution, if so desired, may be accomplished at a later point in the synthesis of the compounds of Formula I by techniques known to those of ordinary skill in the art.
Compound III of Scheme I may be prepared as known to those of ordinary skill in the art. For example, 3,3-difluoropyrrolidine hydrochloride may be prepared as described by Giardina, G et al. Svnlett. 1995, 55. 3,3,4,4-tetrafluoropyrrolidine may be prepared as described in Chaudry et al. J. Chem. Soc. 1964, 874. Alternatively, 3,3,4,4-tetrafluoropyrrolidine may be prepared as depicted below in Scheme II.
SCHEME
HO
Figure imgf000015_0001
X XI
NH2R
w3 "Deprotection"
Figure imgf000015_0003
Figure imgf000015_0002
According to Scheme II, in Step 1 , the hydroxyl groups of 2,2,3,3- tetrafluorobutanediol (X) are activated to a leaving group, R8, (wherein R8 may be Br, I or SO2R11, wherein R11 may either be (1) a C C8 straight or branched alkyl, optionally substituted with one or several fluorines or (2) an aryl group, optionally substituted with halogen or a
Figure imgf000016_0001
straight or branched alkyl optionally substituted with one to four fluorines). Preferably, however, R8 is a trifluoromethylsulfonyloxy radical (F3CSO3). The activating reagents necessary to transform the alcohol function to, for example, bromine or iodine are well-known to those skilled in the art (see e.g. March, Advanced Organic Chemistry, 3rd ed. pp. 382-384 and Larock, Comprehensive Organic Transformations, pp. 353-360, incorporated by reference) and include, but are not limited to, the following activating reagents: hydrogen bromide ("HBr"), phosphorus tribromide ("PBr3"), phosphorus pentabromide ("PBr5"), thionyl bromide ("SOBr2") and hydrogen iodide ("HI"). Preferred activating reagent combinations are triphenylphosphine/carbon tetrabromide ("Ph3P/CBr4"), Ph3P/N- bromosuccinimide, potassium iodide/phosphoric acid ("KI/H3PO4"), Ph3P/l2 and Me3SiCI/Nal. Activation of the alcohol function to an alkyl or arylsulfonate is accomplished by reaction with the corresponding sulfonyl chloride or sulfonic anyhydride in an inert solvent in the presence of a base, such as pyridine or triethylamine, which is cooled (0"C) and stirred for about one hour. The reaction mixture is then stirred at room temperature for about an additional hour.
In Step 2, the reaction of compound XI with a primary amine R9NH2, wherein R9 is an alkyl or aryl "protecting" group (i.e., such that the bond linking R9 to the nitrogen atom may be easily cleaved by standard chemical manipulation known to those skilled in the art in Step 3), is accomplished by heating the solution to reflux overnight. Examples of N-protecting groups are described in "Protective Groups in Organic Synthesis", 2nd. Ed., P.G.M. Wuts and T.W. Greene, p.362, incorporated herein by reference, and include, for example, benzyl, te/τ-butyl, allyl and benzhydryl. Preferably, R9 is benzyl, in which case the deprotection, Step 3, is performed by hydrogenolysis in the presence of palladium.
Step 3 can be performed on a cationic salt of intermediate compound XII, such as hydrochloride, hydrobromide, acetate, trifluoroacetate etc., in an appropriate solvent (e.g. water, methanol or ethanol). Removal of the R9 protecting group from compound XII may be accomplished under conditions appropriate for the particular R9 protecting group in use. Such conditions include, for example, (a) hydrogenolysis where R9 is benzyl or benzhydryl; (b) treatment with a strong acid, such as trifluoroacetic acid or hydrochloric acid, wherein R9 is te/t-butyl; or (c) treatment with tributyltinhydride and acetic acid in the presence of catalytic bis(triphenylphosphine) palladium (II) chloride where R9 is allyl.
If R9 is benzyl, deprotection is performed by hydrogenolysis in the presence of 10% palladium in ethanol at about 45 psi for about 3 hours. The final compound III is, thus, isolated as the corresponding cationic salt by filtration of the catalyst over diatomaceous earth, removal of the solvent and trituration with a non- hydroxylic solvent, such as diethyl ether, diisopropyl ether, ethyl acetate, 1 ,4- dioxane or tetrahydrofuran. Compound III is utilized, as described above in Scheme I, for preparation of DPP-IV inhibitor compounds of Formula I.
SCHEME III
1 Coupling Agent
Figure imgf000017_0001
Figure imgf000017_0002
V VI
Et2NSF3
3 Deprotection
Figure imgf000017_0003
Figure imgf000017_0004
1 VII
Alternatively, compounds of Formula I, wherein a and b are each 0, may be prepared in accordance with the steps of Scheme III. In Step 1 of Scheme III, (L) amino acid compound of Formula II (e.g. (Z-)-Boc-isoleucine), wherein R7 and R10 are defined above, is coupled with hydroxyazetidine (the compound of Formula V), as analogously described above in step 1 of Scheme I, forming a compound of Formula VI. The resulting compound of Formula VI is treated, in Step 2, with diethylaminosulfur trifluoride or a similar fluorinating agent, providing a compound of Formula VII. In Step 3, a compound of Formula VII is treated with acid, as analogously described above in Step 2 of Scheme I, providing a compound of Formula I, wherein a and b are each zero. The reaction described in Step 2 is readily accomplished by cooling a solution of diethylaminosulfur trifluoride (e.g. -78°C) in a reaction inert solvent (e.g. dichloromethane) to which a solution of the compound of Formula VI is added dropwise. The reaction mixture is warmed to ambient temperatures, until the starting materials are no longer present or until the reaction is completed, as determined by thin layer chromatography or other analytical techniques well known to those skilled in the art. The compound of Formula VII may be isolated according to methods well known to those skilled in the art and further treated with gaseous acid in Step 3, as analogously described above in Step 2 of Scheme I.
Similarly, monofluoro pyrrolidine and piperidine derivatives can be prepared by a similar sequence, starting respectively with pyrrolidin-3-ol or a hydroxypiperidine.
SCHEME IV
Coupling Agent
Figure imgf000018_0001
VIM
2 Deprotection
Figure imgf000018_0002
Figure imgf000018_0003
IX
Alternatively, compounds of Formula I can be prepared according to Scheme IV. In Step 1 , (L) amino acid compounds of Formula II (e.g. (L)-Boc- isoleucine, Boc-cyclohexylglycine etc.), wherein R7 and R10 are defined above, may be coupled with a compound of Formula VIII, a fluorinated piperidine, wherein R1, R2, R3, R4, R5and R6 are defined above, (e.g. 4,4-difluoro-piperidine hydrochloride), as analogously described above in Step 1 of Scheme I, forming the compound of Formula IX. The compound of Formula IX, in Step 2, may be deprotected (e.g. gaseous acid), as analogously described in Step 2 of Scheme I, providing the compound of Formula I.
It will be recognized by a person skilled in the art that the synthetic sequence used in Schemes I and 4 can be applied to the synthesis of analogous compounds containing an azetidine ring in lieu of the pyrrolidine or piperidine moiety, starting with the requisite azetidine starting material.
One of ordinary skill in the art will appreciate that the protected (L) amino acid compounds of Formula II depicted in Schemes I, 3 and 4, and exemplified in Examples 1-16, may be replaced with a racemic mixture of a compound of Formula II. Consequently, the compounds of Formula I may exist as racemic mixtures of enantiomers and these mixtures are within the scope of this invention.
The optically active amino acids may be obtained by resolution or by asymmetric synthesis or by other methods well known to those skilled in the art, prior to coupling in Step 1 of Schemes I, III and IV. Alternatively, resolution, if so desired, may be accomplished at a later point in the synthesis of the compounds of Formula I by techniques known to those of ordinary skill in the art.
The compounds of Formula I of the present invention are useful for the treatment of dipeptidyl peptidase-IV related conditions; the treatment of type II diabetes; the prevention of disease progression in type II diabetes; the treatment of type I diabetes, impaired glucose tolerance, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy and nephropathy, Metabolic Syndrome, obesity, the treatment of hypertension, hyperlipidemia, metabolic acidosis, arthritis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, short stature due to growth hormone deficiency, infertility due to polycystic ovary syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and short bowel syndrome.
The invention also relates to therapeutic methods for treating or preventing the above described conditions in a mammal, including a human, wherein a compound of Formula I of this invention is administered as part of an appropriate dosage regimen designed to obtain the benefits of the therapy. The appropriate dosage regimen, the amount of each dose administered and the intervals between doses of the compound will depend upon the compound of Formula I of this invention being used, the type of pharmaceutical compositions being used, the characteristics of the subject being treated and the severity of the conditions.
In general, an effective dosage for the compounds of Formula I described above is in the range of 0.01 mg/kg/day to 30 mg/kg/day, preferably 0.01 mg/kg/day to 1 mg/kg/day in single or divided doses. Some variation in dosage will necessarily occur, however, depending on the condition of the subject being treated. The individual responsible for dosing will, in any event, determine the appropriate dose for the individual subject. The compounds of Formula I of this invention may be administered to a subject in need of treatment by a variety of conventional routes of administration, including orally and parenterally, (e.g., intravenously, subcutaneously or intramedullary). Further, the pharmaceutical compositions of this invention may be administered intranasally, as a suppository or using a "flash" formulation, i.e., allowing the medication to dissolve in the mouth without the need to use water.
The compounds of this invention may be administered in single (e.g., once daily) or multiple doses or via constant infusion. The compounds of this invention may also be administered alone or in combination with pharmaceutically acceptable carriers, vehicles or diluents, in either single or multiple doses. Suitable pharmaceutical carriers, vehicles and diluents include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents. The pharmaceutical compositions formed by combining the compounds of this invention and the pharmaceutically acceptable carriers, vehicles or diluents are then readily administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, injectable solutions and the like. These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like.
Thus, for purposes of oral administration, tablets containing various excipients such as sodium citrate, calcium carbonate and/or calcium phosphate may be employed along with various disintegrants such as starch, alginic acid and/or certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and/or acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the active pharmaceutical agent therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and/or combinations thereof.
For parenteral administration, solutions of the compounds of this invention in sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solutions may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art. For intranasal administration or administration by inhalation, the compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of a compound of this invention. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound or compounds of the invention and a suitable powder base such as lactose or starch.
Since the present invention has an aspect that relates to treatment of the above-described indications by treatment with a combination of compounds that may be co-administered separately, the invention also relates to combining separate pharmaceutical compositions in kit form. The kit comprises two separate compositions: (1 ) a first dosage form comprising a compound of Formula I, a prodrug thereof, or pharmaceutically acceptable salts and prodrugs, plus a pharmaceutically acceptable diluent or carrier; and (2) a second dosage form comprising an antidiabetic agent selected from insulin and insulin analogs; insulinotropin; biguanides; σ2-antagonists and imidazolines; glitazones; aldose reductase inhibitors; glycogen phosphorylase inhibitors; sorbitol dehydrogenase inhibitors; fatty acid oxidation inhibitors; σ-glucosidase inhibitors; ff-agonists; phosphodiesterase inhibitors; lipid-lowering agents; antiobesity agents; vanadate and vanadium complexes and peroxovanadium complexes; amylin antagonists; glucagon antagonists; growth hormone secretagogues; gluconeogenesis inhibitors; somatostatin analogs; inhibitors of renal glucose; antilipolytic agents; prodrugs of the second dosage form and pharmaceutically acceptable salts of the second dosage form and the prodrugs, plus a pharmaceutically acceptable carrier or diluent. The amounts of (1 ) and (2) are such that, when co-administered, the conditions, as described above, is treated or remediated. The kit comprises a container for containing the separate dosage forms, such as a divided bottle or a divided foil packet, wherein each compartment contains a plurality of dosage forms (e.g. tablets) comprising (1 ) or (2). Alternatively, rather than separating the active ingredient-containing dosage forms, the kit may contain separate compartments, each of which contains a whole dosage that in turn comprises separate dosage forms.
An example of this type of kit is a blister pack wherein each individual blister contains two (or more) tablet(s) comprising pharmaceutical composition dosage form (1), and dosage form (2). Typically, the kit comprises directions to the administration of the separate components. The kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g. oral and parenteral), are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.
In the case of the instant invention, a kit, therefore, comprises: d) a first dosage form comprising a compound of Formula I, a prodrug thereof, or a pharmaceutically acceptable salt or prodrug; e) a second dosage form comprising an antidiabetic agent selected from insulin and insulin analogs; insulinotropin; biguanides; σ2-antagonists and imidazolines; glitazones; aldose reductase inhibitors; glycogen phosphorylase inhibitors; sorbitol dehydrogenase inhibitors; fatty acid oxidation inhibitors; σ-glucosidase inhibitors; /ff-agonists; phosphodiesterase inhibitors; lipid-lowering agents; antiobesity agents; vanadate and vanadium complexes and peroxovanadium complexes; amylin antagonists; glucagon antagonists; growth hormone secretagogues; gluconeogenesis inhibitors; somatostatin analogs; inhibitors of renal glucose; antilipolytic agents; prodrugs of the second dosage form and pharmaceutically acceptable salts of the second dosage form and the prodrugs; f) an optional pharmaceutically acceptable carrier or diluent; and g) a container means for containing said first dosage (a), said second dosage (b) and said optional carrier or diluent (c).
Methods of preparing various pharmaceutical compositions with a certain amount of active ingredient are known, or will be apparent in light of this disclosure, to those skilled in this art. For examples of methods of preparing pharmaceutical compositions, see Remington's Pharmaceutical Sciences, Mack Publishing
Company, Easton, Pa., 19th Edition (1995).
In Vitro Assay for Dipeptidyl Peptidase Inhibition
The dipeptidyl peptidase inhibition may be demonstrated in vitro by the following assay, which is adapted from published methods for the measurement of
DPP-IV activity (Assay of dipeptidyl peptidase IV in serum by fluorometry of 4- methoxy-2-naphthylamide. (1988) Scharpe, S., DeMeester, I., Vanhoof, G., Hendriks, D., Van Sande, M., Van Camp, K. and Yaron, A. Clin. Chem. 34:2299-2301 ; Dipeptidyl peptidases of human lymphocytes (1988) Lodja, Z. Czechoslovak Medicine, 11 : 181-194.) Substrate solution, comprising 50 μM Gly-Pro-4-methoxy B naphthylamide HCI (e.g.182 μg Gly-Pro-4-methoxy B naphthylamide HCI per 10 mL 50mM Tris assay buffer pH 7.3 containing 0.1 M sodium chloride, 0.1 % (v/v) Triton and enzyme (Enzyme Systems Products Cat#SPE-01 , DPP-IV 5 mU/mL stock) diluted 1 :100 (100 μL enzyme per 10 mL substrate solution), forming an enzyme substrate solution that is maintained at 4°C. 150 μL of the enzyme substrate solution is pipetted into microtiter wells of a polystyrene 96-well plate, and maintained at 4°C. 5μUwell of compounds of Formula I are added, bringing the final compound of Formula I concentrations to 3 μM - 10 nM per well.
Controls. Enzyme is omitted from four (4) wells, as a reagent blank. 5 μL of 3 mM Diprotin A is added to four wells as a positive quality control, providing a final Diprotin A concentration of 100 μM. To measure total enzyme activity (i.e. a negative control), without the influence of any compounds of Formula I, 5 μL of distilled water is added to four wells.
The entire assay is incubated overnight (about 14-18 hours) at 37°C. The reaction is quenched by adding 10 μL of Fast Blue B solution (0.5 mg/mL Fast Blue B in a buffer comprising 0.1 M sodium acetate pH 4.2 and 10% (v/v) Triton X-100 to each well, followed by shaking for approximately 5 minutes at room temperature.
The plates may be analyzed on a Spectramax spectrophotometer, or equivalent equipment, (absorption maximum at 525 nm). IC50 data for compounds may be obtained by measuring the activity of DPP-IV over a range of compound concentrations from 10nM to 3μM.
Oral glucose tolerance tests ("OGTT") have been in use in humans since, at least, the 1930's, Pincus et al., Am. J. Med. Sci, 188: 782 (1934), and is routinely used in the diagnosis of human diabetes, though, not to evaluate the efficacy of therapeutic agents in patients. KK mice have been used to evaluate glitazones (Fujita et al. Diabetes 32:804-
810 (1983); Fujiwara et al., Diabetes 37: 1549-48 (1988); Izumi et al. Biophar Durg.
Dispos. 18:247-257 (1997)), metformin (Reddi et al. Diabet. Metabl. 19:44-51 (1993)), glucosidase inhibitors (Hamada et al. Jap. Pharmacol. Ther. 17:17-28 (1988); Matsuo et al. Am. J. Clin. Nutr. 55:314S-317S (1992)), and the extra-pancreatic effects of sulfonylureas (Kameda et al Arzenim. Forsch./Drug Res. 32:39044 (1982); Muller et al. Horm. Metabl. Res. 28:469-487 (199)).
KK mice are derived from an inbred line first established by Kondo et al.
(Kondo et al. Bull. Exp. Anim. 6:107-112 (1957)). The mice spontaneously develop a hereditary form of polygenic diabetes that progresses to cause renal, retinal and neurological complications analogous to those seen in human diabetic subjects, but they do not require insulin or other medication for survival.
The invention is directed to the use of KK mice to evaluate the effects of insulin secretagogue agents in the context of an oral glucose tolerance test. In Vivo Assay for Glucose Lowering The glucose lowering effects of DPP-IV inhibitors, compounds of Formula I, may be exemplified in 4-6 week old KK/H1 J mice (Jackson Labs) in the context of an oral glucose tolerance test. The mice are fasted overnight (about 14-18 hours), but allowed free access to water. After fasting, (time ("t" = 0), 25 μL of blood is drawn from the retro-orbital sinus and added to 0.025% heparinized saline (100 μL) on ice. The mice (10 per group) are then orally dosed with a solution of a compound of Formula I in 0.5% methylcellulose (0.2 mL/mouse). Two controls groups receive only 0.5% methylcellulose. At t = 15 minutes, the mice are bled, as described above, and then dosed with 1 mg/kg glucose in distilled water (0.2 mL/mouse). The first control group is dosed with glucose. The second control group is dosed with water. At t = 45 minutes, the mice are again bled, as described above. The blood samples are centrifuged, the plasma collected and analyzed for glucose content on a Roche- Hitachi 912 glucose analyzer. The data may be expressed as percent (%) inhibition of glucose excursion relative to the two control groups (i.e. the glucose level in the animals receiving glucose but no test compound representing 0% inhibition and the glucose concentration in the animals receiving only water representing 100% inhibition).
GENERAL EXPERIMENTAL PROCEDURES
Melting points were determined on a Thomas Scientific capillary melting point apparatus, and are uncorrected.
Flash chromatography was performed according to the method described by W.C. Still et al. in J. Org. Chem. 1978, 43, 2923. The examples below are intended to illustrate particular embodiments of the invention and are not intended to limit the specification, including the claims, in any manner. The compounds exemplified hereinafter, Examples 1-16, displayed in vitro activity with an IC50 (concentration of test compound required for 50% inhibition) of at or below 3 μM. Example 1 (2S, 3S)-2-amino-3-methyl-1-(3.3.4.4-tetrafluoro-pyrrolidin-1-yl)-pentan-1-one
Step 1 : 1S, 2S.-2-MethvM-(3.3.4.4-tetrafluoro-pyrroMdine-1-carbonyl,-butyll- carbamic acid tert-butyl ester.
To a mixture of ( )-Boc-isoleucine (322 mg, 1.30 mmol), 3,3,4,4-tetrafluoropyrrolidine hydrochloride (300 mg, 1.67 mmol), hydroxybenzotriazole (225 mg, 1.67 mmol) and triethylamine (0.23 mL, 1.67 mmol) in dichloromethane (10 mL) was added 1-(-3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (319 mg, 1.67 mmol). The mixture was stirred at room temperature overnight, diluted with ethyl acetate, washed with 2 N HCI, saturated sodium bicarbonate solution, water and brine, dried over magnesium sulfate and concentrated. The product was purified by flash-chromatography (hex / ethyl acetate, 4:1) and isolated as a white solid (415 mg, 86%). The 3,3,4,4-tetrafluoro-pyrrolidine hydrochloride utilized in Step 1 may be prepared according to Chaudhry et al. J.Chem.Soc; 1964; 874. Alternatively, the fluorinated pyrrolidine may be prepared as described in Scheme II. Step 2: (2S, 3S)-2-amino-3-methyl-1-(3,3,4.4-tetrafluoro-pyrrolidin-1-yl)-pentan- 1-one hydrochloride. [(1S, 2S)-2-Methyl-1-(3,3,4,4-tetrafluoro-pyrrolidine-1-carbonyl)-butyl]- carbamic acid tert-butyl ester (200 mg, 0.56 mmol) was dissolved in ethyl acetate (4 mL), cooled to 0°C and treated with gaseous HCI for about 1 minute. After 15 minute at 0°C and 30 minute at room temperature, the mixture was concentrated to dryness and the solid was triturated with hexane, collected and dried under vacuum overnight (124 mg, 76%, mp > 250 °C).
Example 2 (2S, 3S) -2-amino-1 -(3-fluoro-azetidin-1 -yl)-3-methyl-pentan-1 -one.
Step 1 : r(7S,2S)-1-(3-Hvdroxy-azetidine-1-carbonyl,-2-methyl-butyll-carbamic acid te/f-butyl ester.
[(7S,2S)-1-(3-Hydroxy-azetidine-1-carbonyl)-2-methyl-butyl]-carbamic acid te/f-butyl ester was prepared as analogously described in Step 1 of Example 1 from a mixture of (L)-Boc-isoleucine and 3-hydroxyazetidine. 3-Hydroxyazetidine was prepared according to Lee, J. et al. (Bioorg.Med.Chem.Lett. 2000, 10, 1063). Step 2: \(1S, 2S)-1-(3-Fluoro-azetidine-1-carbonyl)-2-methyl-butyll-carbamic acid te f-butyl ester.
To a cooled (-78°C) solution of diethylaminosulfur trifluoride (0.46 mL, 3.5 mmol) in dichloromethane (6 mL), was added dropwise a solution of [(1S, 2S)-1-(3- hydroxy-azetidine-1 -carbonyl)-2-methyl-butyl]-carbamic acid te/f-butyl ester (1.0 g, 3.5 mmol) in dichloromethane (4 mL). The mixture was warmed to room temperature, stirred overnight, then diluted with ethyl acetate and poured into ice/water. The layers were separated, and the organic phase washed with water and brine, dried over magnesium sulfate and concentrated. The product was purified by flash-chromatography (ethyl acetate) and isolated as an oil (250 mg, 25%). Step 3: (2S,3S.-2-amino-1 -(3-fluoro-azetidin-1 -yl) -3-methyl-pentan-1 -one. (2S,3S)-2-amino-1-(3-fluoro-azetidin-1-yl)-3-methyl-pentan-1-one was prepared by HCI treatment of [(7S,2S)-1-(3-fluoro-azetidine-1-carbonyl)-2-methyl- butylj-carbamic acid te/f-butyl ester as analogously described in Step 2 of Example 1. (mp 208-210 °C).
Example 3 (S)-2-amino-2-cvclohexyl-1-(3.3.4.4-tetrafluoro-pyrrolidin-1-yl)-ethanone
Step 1 : (SH1-Cvclohexyl-2-oxo-2-,3.3A4-tetrafluoro-pyrrolidin-1-yl)-ethyll- carbamic acid te/f-butyl ester.
(S -[1-Cyclohexyl-2-oxo-2-(3,3,4,4-tetrafluoro-pyrrolidin-1-yl)-ethyl]-carbamic acid te/f-butyl ester was prepared from (Z.)-Boc-cyclohexylglycine and 3,3,4,4- tetrafluoropyrrolidine as analogously described in Step 1 of Example 1. Step 2: ι'S)-2-amino-2-cvclohexyl-1-(3 4 tetrafluoro-pyrrolidin-1-yl)-ethanone. (S)-2-amino-2-cyclohexyl-1-(3,3,4,4-tetrafluoro-pyrrolidin-1-yl)-ethanone was obtained by HCI treatment of S)-[1-cyclohexyl-2-oxo-2-(3,3,4,4-tetrafluoro-pyrrolidin- 1-yl)-ethyl]-carbamic acid te/f-butyl ester as analogously described in Step 2 of Example ! (mp 278 °C). Example 4 (2S.3R.-2-amino-3-methyl-1-.3,3,4.4-tetrafluoro-pyrrolidin-1-yl.-pentan-1-one
Step 1 : \(1 S.2/?.-2-Methyl-1 -(3.3.4.4-tetraf luoro-pyrrolidine-1 -carbonyl.-butyll- carbamic acid te/f-butyl ester.
[(7S,2R)-2-Methyl-1-(3,3,4,4-tetrafluoro-pyrrolidine-1-carbonyl)-butyl]- carbamic acid te/f-butyl ester was prepared as analogously described in Step 1 of Example 1 from (L)-Boc-allo-isoleucine and 3,3,4,4-tetrafluoropyrrolidine. Step 2: (2S, 3fl.-2-amino-3-methyl-1-(3.3.4.4-tetrafluoro-pyrrolιdin-1-yl)-pentan- 1-one
(2S,3/:?J-2-amino-3-methyl-1-(3,3,4,4-tetrafluoro-pyrrolidin-1-yl)-pentan-1-one was prepared by HCI treatment of [(1S, 2R)-2-methyl-1-(3,3,4,4-tetrafluoro-pyrrolidine-
1-carbonyl)-butyl]-carbamic acid te/f-butyl ester as analogously described in Step 2 of
Example 1. (mp > 250 °C).
Example 5
(S)-2-amino-2-cyclohexyl-1 -(3-f luoro-azetidin-1 -yl)-ethanone
(S)-2-amino-2-cyclohexyl-1 -(3-fluoro-azetidin-1 -yl)-ethanone was synthesized from 3-azetidinol hydrochloride and (L)-Boc-cyclohexylglycine as analogously described in Example 2 (mp 238-240 °C).
Example 6 (S)-2-amino-3-methyl-1 -(3.3.4.4-tetraf luoro-pyrrolidin-1 -yl)-butan-1 -one
(S)-2-amino-3-methyl-1-(3,3,4,4-tetrafluoro-pyrrolidin-1-yl)-butan-1-one was prepared from (Z-)-Boc-valine and 3,3,4,4-tetrafluoropyrrolidine as analogously described in Example 1 (mp 234-238 °C).
Example 7 f2S,3 ?)-2-amino-1 -(3.3-difluoro-pyrrolidin-1 -yl)-3-methyl-pentan-1 -one
(2S,3R)-2-amino-1-(3,3-difluoro-pyrrolidin-1-yl)-3-methyl-pentan-1-one was prepared from 3,3-difluropyrrolidine hydrochloride (prepared according to Giardina, G. Synlett 1995, 55) and ( )-Boc-isoleucine, as analogously described in Example 1 (mp 196-198 °C).
Example 8
(2S.3S.-2-amino-1-(3,3-difluoro-pyrrolidin-1-yl.-3-methyl-pentan-1-one
(2S, 3S)-2-amino-1 -(3,3-difluoro-pyrrolidin-1 -yl)-3-methyl-pentan-1 -one was prepared from 3,3-difluropyrrolidine hydrochloride and ( )-Boc-isoleucine, as analogously described in Example 7 (mp 195-198 °C).
Example 9 (S)-2-amino-4-methyl-1-(3,3.4.4-tetrafluoro-pyrrolidin-1-v0-pentan-1-one hydrochloride
(S)-2-amino-4-methyl-1 -(3,3,4,4-tetrafluoro-pyrrolidin-1 -yl)-pentan-1 -one hydrochloride was prepared from (Z-)-Boc-leucine and 3,3,4,4 tetrafluoropyrrolidine hydrochloride, as analogously described in Example 1 (mp > 250 °C).
Example 10
(S)-2-amino-2-cyclohexyl-1 -(3.3-dif luoro-azetidin-1 -yl)-ethanone hydrochloride
(S)-2-amino-2-cyclohexyl-1 -(3,3-difluoro-azetidin-1 -yl)-ethanone hydrochloride was prepared by coupling 3,3-difluoro-azetidine hydrochloride (as described in WO 0047582) with Boc-(Z_)-cyclohexylglycine, followed by HCI deprotection as described in Example 1 (mp 220°C dec). Example 11 (S)-2-amino-1-(3.3-difluoro-azetidin-1-yl)-3-methyl-pentan-1-one hydrochloride
(S)-2-amino-1-(3,3-difluoro-azetidin-1-yl)-3-methyl-pentan-1-one hydrochloride was prepared by coupling 3,3-difluoro-azetidine hydrochloride (WO 0047582) with Boc-(Z-)-isoleucine followed by HCI deprotection as analogously described in Example 1 (mp 195°C dec).
Example 12 (S)-2-amino-2-cvclohexyl-1 -(4.4-difluoro-piperidin-1 -yl.-ethanone hydrochloride
4,4-Difluoro-piperidine hydrochloride, obtained by HCI treatment of 4,4- difluoro-piperidine-1-carboxylic acid tert-butyl ester (as described in WO0040561 ), was coupled with Boc-( .)-cyclohexylglycine followed by HCI deprotection, as analogously described in Example 1 (mp > 250 °C).
Example 13 (S)-2-amino-1 -(4.4-dif luoro-piperidin-1 -yl.-3-methyl-pentan-1 -one hydrochloride
(S)-2-amino-1 -(4,4-difluoro-piperidin-1 -yl)-3-methyl-pentan-1 -one hydrochloride was prepared from 4,4-difluoro-piperidine hydrochloride and Boc-(L)- isoleucine as described in Example 1 (mp 190-192°C).
Example 14 (S,-2-amino-1 -(3.3.4.4-tetrafluoro-pyrrolidin-1 -yl)-propan-1 -one hydrochloride
(S)-2-amino-1-(3,3,4,4-tetrafluoro-pyrrolidin-1-yl)-propan-1-one hydrochloride was prepared from Boc-(Z_)-alanine and 3,3,4,4-tetrafluoropyrrolidine as analogously described in Example 1 (mp > 250°C).
Alternative preparation of 3,3,4,4-tetrafluoropyrrolidine hydrochloride
Step 1 : Trifluoro-methanesulfonic acid 2.2,3.3-tetrafluoro-4-(trifluoro- methanesulfonyloxy)-butyl ester.
To a cooled (0°C ) solution of 2,2,3,3-tetrafluorobutanediol (15 g, 93 mmol) and pyridine (19 mL, 230 mmol) in dichloromethane (250 mL), was added dropwise trifluoromethanesulfonic anhydride (34 mL, 200 mmol). After the addition, the mixture was stirred at 0°C for one hour, followed by stirring at room temperature for one additional hour, then diluted with dichloromethane, washed with water and brine, dried over magnesium sulfate, filtered and concentrated to near dryness, leaving a dichloromethane-containing oil. Step 2: 1-Benzyl-3.3.4.4-tetrafluoro-pyrrolidine hydrochloride
A solution of the crude trifluoro-methanesulfonic acid 2,2,3,3-tetrafluoro-4- (trifluoro-methanesulfonyloxy)-butyl ester, benzylamine (10 mL, 93 mmol) and triethylamine (33 mL, 230 mmol) in ethanol (230 mL) was heated to reflux overnight. The mixture was concentrated to about one-third of its volume, diluted with ether, washed with 1 N sodium hydroxide, water and brine, dried over magnesium sulfate, filtered and concentrated to an oil. The oil was redissolved in ether, cooled to 0 °C and saturated with hydrogen chloride. The precipitate was collected and dried (23.8 g, 95%, (mp 139-143 °C). Step 3: 3.3.4.4-Tetrafluoro-pyrrolidine hydrochloride. A solution of 1-benzyl-3,3,4,4-tetrafluoro-pyrrolidine hydrochloride (23.8 g, 88 mmol) in ethanol (300 mL) containing 10% palladium on carbon was treated with hydrogen in a Parr shaker at 45 psi for 3 hours. The mixture was filtered through Celite®, the filtrate was concentrated to dryness. The residue was triturated with ether and the solid was collected and dried (13.4 g, 85%, (mp 193-196 °C).

Claims

1. A compound of the Formula I,
Figure imgf000032_0001
a prodrug thereof, or a pharmaceutically acceptable salt of the compound or the prodrug, wherein:
R1 is 3-fluoroazetidin-1-yl, 3,3-difluoroazetidin-1-yl, 3,4-difluoropyrrolidin-1-yl, 3,3,4- trifluoropyrrolidin-1-yl, 3,3,4,4-tetrafluoropyrrolidin-1-yl, 3-fluoropiperidin-1-yl, 4- fluoropiperidin-1-yl, 3,4-difluoropiperidin-1-yl, 3,5-difluoropiperidin-1-yl, 3,3- difluoropiperidin-1-yl, 4,4-difluoropiperidin-1-yl, 3,4,5-trifluoropiperidin-1-yl, 3,3,4- trifluoropiperidin-1 -yl, 3,3,5-trifluoropiperidin-1 -yl, 3,4,4-trifluoropiperidin-1 -yl, 3,3,4,5- tetrafluoropiperidin-1-yl, 3,4,4,5-tetrafluoropiperidin-1-yl, 3,3,4,4-tetrafluoropiperidin-1- yl 3,3,5,5-tetrafluoropiperidin-1-yl, 3,3,4,5,5-pentafluoropiperidin-1-yl, 3,3,4,4,5- pentafluoropiperidin-1-yl or 3,3,4,4,5,5-hexafluoropiperidin-1-yl; and R2 is (C C8)alkyl or (C3-C8)cycloalkyl.
2. A compound of Claim 1 wherein R1 is 3-fluoroazetidin-1-yl or 3,3- difluoroazetidin-1-yl.
3. A compound of Claim 1 wherein R1 is 3,4-difluoropyrrolidin-1-yl, 3,3,4- trifluoropyrrolidin-1-yl, 3,3,4,4-tetrafluoropyrrolidin-1-yl. 4. A compound of Claim 1 wherein R1 is 3-fluoropiperidin-1-yl, 4- fluoropiperidin-1-yl, 3,4-difluoropiperidin-1-yl, 3,5-difluoropiperidin-1-yl, 3,3- difluoropiperidin-1-yl or 4,
4-difluoropiperidin-1-yl.
5. A compound of Claim 1 wherein R1 is 3,4,5-trifluoropiperidin-1-yl, 3,3,4-trifluoropiperidin-1-yl, 3,3,5-trifluoropiperidin-1-yl, 3,4,4-trifluoropiperidin-1-yl, 3,3,4,5-tetrafluoropiperidin-1-yl, 3,4,4,5-tetrafluoropiperidin-1-yl, 3,3,4,4- tetrafluoropiperidin-1-yl 3,3,5,5-tetrafluoropiperidin-l-yl, 3,3,4,5,5- pentafluoropiperidin-1-yl, 3,3,4,4,5-pentafluoropiperidin-1-yl or 3,3,4,4,5,5- hexafluoropiperidin-1 -yl.
6. A compound of Claim 1 which is (2S,3S)-2-amino-3-methyl-1-(3,3,4,4-tetrafluoro-pyrrolidin-1-yl)-pentan-1- one hydrochloride;
(2S,3S)-2-amino-1-(3-fluoro-azetidin-1-yl)-3-methyl-pentan-1-one hydrochloride; (S)-2-amino-2-cyclohexyl-1 -(3,3,4,4-tetrafluoro-pyrrolidin-1 -yl)-ethanone hydrochloride;
(2S,3R)-2-amino-3-methyl-1-(3,3,4,4-tetrafluoro-pyrrolidin-1-yl)-pentan-1- one hydrochloride;
(S)-2-amino-2-cyclohexyl-1 -(3-fluoro-azetidin-1 -yl)-ethanone hydrochloride;
(S)-2-amino-3-methyl-1 -(3,3,4,4-tetrafluoro-pyrrolidin-1 -yl)-butan-1 -one hydrochloride;
(S)-2-amino-4-methyl-1 -(3,3,4,4-tetrafluoro-pyrrolidin-1 -yl)-pentan-1 -one hydrochloride; (S)-2-amino-2-cyclohexyl-1 -(3,3-difluoro-azetidin-1 -yl)-ethanone hydrochloride;
(2S,3S)-2-amino-1-(3,3-difluoro-azetidin-1-yl)-3-methyl-pentan-1-one hydrochloride;
(S)-2-amino-2-cyclohexyl-1-(4,4-difluoro-piperidin-1-yl)-ethanone hydrochloride;
(2S,3S)-2-amino-1 -(4,4-difluoro-piperidin-1 -yl)-3-methyl-pentan-1 -one hydrochloride;
(S)-2-amino-1 -(3,3,4,4-tetrafluoro-pyrrolidin-1 -yl)-propan-1 -one hydrochloride; (S)-2-amino-1 -(3,3-difluoro-azetidin-1 -yl)-3-methyl-butan-1 -one hydrochloride;
(S)-2-amino-1 -(3-fluoro-azetidin-1 -yl)-3-methyl-butan-1 -one hydrochloride;
(2S,3R)-2-amino-1-(3-fluoro-azetidin-1-yl)-3-methyl-pentan-1-one hydrochloride; (2S,3f?)-2-amino-1 -(3,3-difluoro-azetidin-1 -yl)-3-methyl-pentan-1 -one hydrochloride;
(S)-2-amino-2-cyclopentyl-1-(3,3-difluoro-azetidin-1-yl)-ethanone hydrochloride; (S)-2-amino-2-cyclopentyl-1 -(3-fluoro-azetidin-1 -yl)-ethanone hydrochloride; or
(S)-2-amino-2-cyclopentyl-1-(3,3,4,4-tetrafluoro-pyrrolidin-1-yl)-ethanone hydrochloride.
7. A compound of Claim 1 wherein the compound of Formula I,
Figure imgf000034_0001
is a S enantiomer, as shown.
8. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 , a prodrug thereof or a pharmaceutically acceptable salt of the compound or the prodrug, and a pharmaceutically acceptable diluent or carrier.
9. A pharmaceutical composition comprising a therapeutically effective amount of a first compound of Claim 1 , a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prordrug; and a second compound which is insulin or an insulin analog; insulinotropin; a biguanide; an σ2-antagonist or an imidazoline; a glitazone; an aldose reductase inhibitor; a glycogen phosphorylase inhibitor; a sorbitol dehydrogenase inhibitor; a fatty acid oxidation inhibitor; an σ-glucosidase inhibitor; a ^-agonist; a phosphodiesterase inhibitor; a lipid-lowering agent; an antiobesity agent; vanadate, a vanadium complex or a peroxovanadium complex; an amylin antagonist; a glucagon antagonist; a growth hormone secretagogue; a gluconeogenesis inhibitor; a somatostatin analog; an inhibitor of renal glucose; or an antilipolytic agent; a prodrug of the second compound or a pharmaceutically acceptable salt of the second compound or of the prodrug of the second compound.
10. A composition of Claim 9 further comprising a pharmaceutically acceptable carrier or diluent.
11. A therapeutic method of inhibiting dipeptidyl peptidase-IV in a mammal, the method comprising administering to said mammal in need of inhibition of dipeptidyl peptidase-IV a therapeutically effective amount of a compound of Claim 1 , a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug.
12. A method of treating a condition mediated by dipeptidyl peptidase-IV inhibition in a mammal, the method comprising administering to said mammal suffering from a condition mediated by dipeptidyl peptidase-IV inhibition a therapeutically effective amount of a compound of Claim 1 , a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug.
13. The method of Claim 12 wherein the condition treated is Type 2 diabetes, metabolic syndrome, hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, a condition exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, disease progression in Type 2 diabetes, chronic fatigue, epilepsy, a disease associated with intestinal motility, ulcer, irritable bowel syndrome, inflammatory bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, an eating disorder, chronic pain or alcohol addiction.
14. The method of Claim 13 wherein the condition treated is Type 2 diabetes.
15. A method of identifying whether an agent is a DPP-IV inhibitor, comprising: administering the agent to a fasted, diabetic KK/H1 J mouse; challenging the KK/H1 J mouse with oral glucose; and assessing a response in the mouse to a subsequent oral glucose challenge, wherein said agent may be identified as a treatment for Type 2 diabetes, metabolic syndrome, hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, a condition exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, to prevent disease progression in Type 2 diabetes, anxiety, depression, insomnia, chronic fatigue, epilepsy, an eating disorder, chronic pain, alcohol addiction, a disease associated with intestinal motility, ulcer, irritable bowel syndrome, inflammatory bowel syndrome or short bowel syndrome.
PCT/IB2003/002257 2002-06-04 2003-05-23 Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors WO2003101958A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2003232405A AU2003232405A1 (en) 2002-06-04 2003-05-23 Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors
MXPA04011958A MXPA04011958A (en) 2002-06-04 2003-05-23 Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors.
BR0311608-5A BR0311608A (en) 2002-06-04 2003-05-23 Cyclically fluorinated amides as dipeptidyl peptidase iv inhibitors
CA002487636A CA2487636A1 (en) 2002-06-04 2003-05-23 Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors
JP2004509652A JP2005533771A (en) 2002-06-04 2003-05-23 Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
EP03756085A EP1513808A2 (en) 2002-06-04 2003-05-23 Fluorinated cyclic amides as dipeptidyl peptidase iv inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38615702P 2002-06-04 2002-06-04
US60/386,157 2002-06-04

Publications (2)

Publication Number Publication Date
WO2003101958A2 true WO2003101958A2 (en) 2003-12-11
WO2003101958A3 WO2003101958A3 (en) 2004-04-22

Family

ID=29712235

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/002257 WO2003101958A2 (en) 2002-06-04 2003-05-23 Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors

Country Status (7)

Country Link
EP (1) EP1513808A2 (en)
JP (1) JP2005533771A (en)
AU (1) AU2003232405A1 (en)
BR (1) BR0311608A (en)
CA (1) CA2487636A1 (en)
MX (1) MXPA04011958A (en)
WO (1) WO2003101958A2 (en)

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004098591A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
WO2005116014A1 (en) 2004-05-12 2005-12-08 Pfizer Products Inc. Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
WO2006118127A1 (en) 2005-04-26 2006-11-09 Mitsubishi Tanabe Pharma Corporation Prophylactic/therapeutic agent for abnormalities of sugar/lipid metabolism
WO2007072083A1 (en) 2005-12-23 2007-06-28 Prosidion Limited Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione
EP1815865A1 (en) * 2004-11-08 2007-08-08 Ono Pharmaceutical Co., Ltd. Therapeutic agent for diabetes comprising protease-inhibiting compound
WO2007120702A2 (en) 2006-04-11 2007-10-25 Arena Pharmaceuticals, Inc. Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
EP2116235A1 (en) 2005-01-10 2009-11-11 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
WO2011005929A1 (en) 2009-07-09 2011-01-13 Arena Pharmaceuticals, Inc. Piperidine derivative and its use for the treatment of diabets and obesity
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US7960384B2 (en) 2006-03-28 2011-06-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
US8084605B2 (en) 2006-11-29 2011-12-27 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
CN107892663A (en) * 2017-12-04 2018-04-10 武汉药明康德新药开发有限公司 A kind of synthetic method of 3,3,4,4 4 fluoropyrrolidine
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase
US10555929B2 (en) 2015-03-09 2020-02-11 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
WO2020188299A1 (en) * 2019-03-20 2020-09-24 Atrogi Ab Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy
EP4000630A1 (en) 2014-09-03 2022-05-25 Invex Therapeutics Ltd Elevated intracranial pressure treatment
US11357757B2 (en) 2017-09-13 2022-06-14 Atrogi Ab Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia
US11427539B2 (en) 2017-09-13 2022-08-30 Atrogi Ab Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia
US11648216B2 (en) 2017-09-13 2023-05-16 Atrogi Ab Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia
US11793774B2 (en) 2017-09-13 2023-10-24 Atrogi Ab Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034538A2 (en) * 1994-06-10 1995-12-21 Universitaire Instelling Antwerpen Purification of serine proteases and synthetic inhibitors thereof
WO2002038541A1 (en) * 2000-11-10 2002-05-16 Taisho Pharmaceutical Co., Ltd. Cyanopyrrolidine derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034538A2 (en) * 1994-06-10 1995-12-21 Universitaire Instelling Antwerpen Purification of serine proteases and synthetic inhibitors thereof
WO2002038541A1 (en) * 2000-11-10 2002-05-16 Taisho Pharmaceutical Co., Ltd. Cyanopyrrolidine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AUGUSTYNS KJL LAMBEIR AM BORLOO M DE MEESTER I VEDERNIKOVA I VANHOOF G HENDRIKS D SCHARPE S HAEMERS A: "Pyrrolidides: synthesis and structure-activity relationship as inhibitors of dipeptidyl peptidase IV" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 32, no. 4, 1997, pages 301-309, XP004086653 ISSN: 0223-5234 *

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004098591A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
US7291618B2 (en) 2004-05-12 2007-11-06 Pfizer Inc Therapeutic compounds
WO2005116014A1 (en) 2004-05-12 2005-12-08 Pfizer Products Inc. Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
EP2116541A1 (en) 2004-05-12 2009-11-11 Pfizer Products Incorporated Proline derivatives and their use as dipeptidyl peptidase IV inhibitors
US7465732B2 (en) 2004-05-12 2008-12-16 Pfizer Inc (2S,4S)-4-(piperazin-1-yl)pyrrolidine-2-methanone derivatives
EP1815865A1 (en) * 2004-11-08 2007-08-08 Ono Pharmaceutical Co., Ltd. Therapeutic agent for diabetes comprising protease-inhibiting compound
EP1815865A4 (en) * 2004-11-08 2010-08-25 Ono Pharmaceutical Co Therapeutic agent for diabetes comprising protease-inhibiting compound
EP2116235A1 (en) 2005-01-10 2009-11-11 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
KR101333876B1 (en) * 2005-04-26 2013-11-27 미쓰비시 타나베 파마 코퍼레이션 Prophylactic/therapeutic agent for abnormalities of sugar/lipid metabolism
JPWO2006118127A1 (en) * 2005-04-26 2008-12-18 田辺三菱製薬株式会社 Preventive and / or therapeutic drug for abnormal sugar / lipid metabolism
JP5100375B2 (en) * 2005-04-26 2012-12-19 田辺三菱製薬株式会社 Preventive and / or therapeutic drug for abnormal sugar / lipid metabolism
WO2006118127A1 (en) 2005-04-26 2006-11-09 Mitsubishi Tanabe Pharma Corporation Prophylactic/therapeutic agent for abnormalities of sugar/lipid metabolism
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2007072083A1 (en) 2005-12-23 2007-06-28 Prosidion Limited Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione
US7960384B2 (en) 2006-03-28 2011-06-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2253311A2 (en) 2006-04-11 2010-11-24 Arena Pharmaceuticals, Inc. Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto
WO2007120702A2 (en) 2006-04-11 2007-10-25 Arena Pharmaceuticals, Inc. Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US8084605B2 (en) 2006-11-29 2011-12-27 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
WO2011005929A1 (en) 2009-07-09 2011-01-13 Arena Pharmaceuticals, Inc. Piperidine derivative and its use for the treatment of diabets and obesity
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
EP4000630A1 (en) 2014-09-03 2022-05-25 Invex Therapeutics Ltd Elevated intracranial pressure treatment
US10772865B2 (en) 2015-03-09 2020-09-15 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11400072B2 (en) 2015-03-09 2022-08-02 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US10555929B2 (en) 2015-03-09 2020-02-11 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy
US11357757B2 (en) 2017-09-13 2022-06-14 Atrogi Ab Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia
US11427539B2 (en) 2017-09-13 2022-08-30 Atrogi Ab Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia
US11648216B2 (en) 2017-09-13 2023-05-16 Atrogi Ab Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia
US11793774B2 (en) 2017-09-13 2023-10-24 Atrogi Ab Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase
CN107892663B (en) * 2017-12-04 2019-08-13 武汉药明康德新药开发有限公司 A kind of synthetic method of tetra- fluoropyrrolidine of 3,3,4,4-
CN107892663A (en) * 2017-12-04 2018-04-10 武汉药明康德新药开发有限公司 A kind of synthetic method of 3,3,4,4 4 fluoropyrrolidine
WO2020188299A1 (en) * 2019-03-20 2020-09-24 Atrogi Ab Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia

Also Published As

Publication number Publication date
BR0311608A (en) 2005-02-22
CA2487636A1 (en) 2003-12-11
AU2003232405A8 (en) 2003-12-19
AU2003232405A1 (en) 2003-12-19
EP1513808A2 (en) 2005-03-16
JP2005533771A (en) 2005-11-10
WO2003101958A3 (en) 2004-04-22
MXPA04011958A (en) 2005-03-31

Similar Documents

Publication Publication Date Title
US6710040B1 (en) Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
WO2003101958A2 (en) Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors
US20040110817A1 (en) Dipeptidyl peptidase IV inhibiting fluorinated cyclic amides
US6812350B2 (en) Synthesis of 3,3,4,4-tetrafluoropyrrolidine and novel dipeptidyl peptidase-IV inhibitor compounds
US20050043292A1 (en) Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors
JP3681110B2 (en) N-substituted 2-cyanopyrrolidine
EP1753748B1 (en) Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
WO2005095339A1 (en) Dicyanopyrrolidines as dipeptidyl peptidase iv inhibitors
US20050234065A1 (en) Dipeptidyl peptidase-IV inhibitors
US6790854B2 (en) Diphenylalkylamine derivatives useful as opioid receptor agonists
JPS6058751B2 (en) Proline related compounds and their production method
JP2005500321A (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors
JP2007513910A (en) DPP-IV inhibitor
AU2008258665B2 (en) Prolinamide derivatives as NK3 antagonists
CA2542727A1 (en) Derivatives of n-[phenyl(pyrrolidine-2-yl)methyl]benzamide and n-[(azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics
WO2006008644A1 (en) Antidiabetic compounds
CN105669682B (en) A kind of intermediate of DPP-IV inhibitor
MXPA01005817A (en) N-substituted 2-cyanopyrrolidines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2487636

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/011958

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004509652

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003756085

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003756085

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003756085

Country of ref document: EP